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Abstract 
Background 
Non-invasive prenatal diagnosis (NIPD) is a promising approach that is 
currently being developed. The principle is that fetal material can be detected in 
maternal plasma and potentially enable women to pursue reliable and timely 
prenatal diagnosis, whilst eliminating the risk of miscarriage associated with 
chorionic villus sampling or amniocentesis. However NIPD research has been 
restricted up until now for the diagnosis of Down syndrome due to the low 
concentration of free fetal DNA (ffDNA) in maternal plasma. Various methods 
have been developed in an attempt to increase the concentration of ffDNA. 
Methods 
This study uses COLD-PCR (co-amplification at lower denaturation temperature 
PCR) to analyse potential enrichment of ffDNA over maternal DNA through 
optimization of the critical denaturation temperature (Td), using Real Time-PCR 
in an attempt to selectively enrich smaller fetal DNA fragments. Fake fetal DNA 
was created in two different spike experiments to imitate the natural 
environment of viable ffDNA. One spike experiment used 5% of fake fetal DNA 
in a 95% maternal background to represent levels of ffDNA during early 
pregnancy. The other spike experiment utilized 10% of fake fetal DNA in 90% 
maternal background to denote late pregnancy. Before running COLD-PCR, 
various adjustments took place to find the critical Td at which one could run the 
spike experiment by COLD-PCR. Products of spike experiments were analysed 
on a genetic analyser for fragment analysis. Melt curve analysis was also 
performed for the spike experiment to identify the specificity of each sample at 
each denaturation temperatures. 
Results 
A critical Td (80°C) was identified for the D21S1890 region of chromosome 21 
by COLD-PCR. This temperature does allow enrichment of fetal DNA, as fake 
maternal DNA was undetermined by RT-PCR compared to fake fetal DNA. The 
spike experiments clearly showed amplification of fake fetal DNA from the 
mixture of fake fetal and fake maternal DNA at the critical Td of 80°C. Running 
same samples of spike experiment on the genetic analyser identified peaks 
from all samples at a Td of 95°C, while at a critical Td of 80°C the result showed 
decreased numbers of maternal peaks, regardless of stutter peaks formation. 
Melt curve analysis results clearly identified heteroduplex formation in the 
samples at the critical Td of 80°C.  
Conclusion 
The results represent a good indication for using COLD-PCR in enriching ffDNA 
for detection by RT-PCR. However, as each individual has only two alleles, the 
observed results of multiple peaks for fragment analysis were not expected. 
Further research needs to focus on both eliminating heteroduplex formation and 
stutter peaks. COLD-PCR has the potential to open a new gateway in NIPD for 
aneuploidy detection. This method could be particularly useful in the detection 
of genetic abnormalities in the fetus, in particular Down syndrome and other 
aneuploidies. 
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1 Chapter One 
1.1 Introduction 
Prenatal diagnosis is a part of an established obstetrical practice; however 
conventional methods of prenatal diagnosis to obtain fetal tissues for genetic 
analysis, including amniocentesis and chorionic villus sampling (CVS), are 
invasive and constitute a finite risk to the unborn fetus (Evans and Wapner, 
2005). Currently used screening tests for aneuploidy are based on the 
assessment of fetal sonographic markers and/or the elevation of biochemical 
markers in the maternal circulation during the first and second trimesters. By far 
the most common aneuploidy compatible with life is Down syndrome (DS, 
trisomy 21), in which the fetus inherits an extra copy of chromosome 21. The 
current screening protocol for trisomy 21 is composed of several stages, 
including blood tests for numerous maternal protein markers and a nuchal 
translucency (NT) ultrasound scan of the fetus. Prenatal assessment with 
biochemical markers at 11-13 weeks of gestation, may detect 90-94% of 
pregnancies affected by trisomy 21 at a false positive rate of 5% (Kagan et al., 
2008b). The current gold standard for diagnosis of trisomy 21 is provided by 
invasive sampling of fetal genetic material through CVS or amniocentesis, 
followed by conventional cytogenetic or DNA analysis. However, both 
procedures are associated with an increased risk of fetal loss of about 1%, 
hence they are only recommended for pregnancies with a high risk of fetal 
trisomy 21 (Cochrane et al., 2003). Since 1997, when cell free fetal DNA 
(cffDNA) in maternal circulation was discovered (Lo et al., 1997), the research 
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interest has focused on the development of reliable techniques for non-invasive 
prenatal diagnosis (NIPD) that would allow direct analysis of fetal genetic 
material based on the discovery of cffDNA in the maternal circulation. To date 
cffDNA has been used to identify fetuses where paternally inherited alleles 
require detection, for example, male fetuses or RHD positive fetuses in D 
negative mothers. For conditions where maternal alleles require analysis, this 
has been more challenging due to the high maternal DNA background 
compared to fetal DNA in maternal plasma. This is regarded as the major 
limitation to achieve routine NIPD for the common chromosomal abnormalities 
such as aneuploidy. For the purposes of prenatal diagnosis, detection of 
aneuploidy requires not just detection but also accurate quantification of the 
DNA derived from specific chromosome.  
Results from techniques such as digital PCR, in which enriched single template 
DNA molecules are isolated by dilution and then amplified (Lo et al., 2007a), 
and direct high-throughput shotgun sequencing, in which millions of sequence 
tags are selected across the genome (Fan et al., 2008) suggest extremely high 
accuracy. The use of massively parallel sequencing technologies has shown 
early promise as a method of detection for trisomy 21 (Chiu and Lo, 2011; Faas 
et al., 2012; Dan et al., 2012; Lo, 2012). Efforts to enrich for cffDNA from 
chromosome of interest prior to massively parallel sequencing have been 
described but to date these approaches have not been used for detection of any 
genetic conditions. Sparks et al., (2012) developed a method called digital 
analysis of selected region (DANSRTM), which selectively evaluates specific 
genomic fragments from cfDNA. By enabling selective analysis of cfDNA, 
DANSR would provide more effiecent use of sequencing to evaluate fetal 
aneuploidy. 
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It is considered that minor enrichment of cffDNA from a mixture of maternal free 
DNA and cffDNA may lead to simple detection of ratios of fetal chromosomes 
by digital counting technology (Lo et al., 2007a), and also it would be cheaper 
and quicker, whereas next generation sequencing approach is highly expensive 
and requires substantial technical and bioinformatics input and analysis. In an 
effort to reduce the cost of sequencing, Liao et al., (2011) have demonstrated 
that a solution based target capture system is able to focus the sequencing 
power to selected genomic regions. Such system is able to increase the 
sequencing coverage of the targeted region by over 200-fold. Therefore, target 
enrichment provides a logical approach for more efficient and cost-effective 
massively parallel sequencing because it increases the proportion of informative 
data from the target region.  
Therefore there is a need to find an approach for fetal DNA enrichment. A 
modified form of PCR known as co-amplification at lower denaturation 
temperature (COLD-PCR) was reported by (Li et al., 2008). COLD-PCR could 
selectively amplify minority alleles from background of wild type allele. It exploits 
subtle difference in the melting temperature (Tm) of variant and mismatched 
sequences compared to wild-type ones and uses a critical denaturation 
temperature (Tc) lower than the melting temperature to selectively amplify 
minority mutated alleles in a wild-type allele background. Li et al (2008) 
suggested that COLD-PCR could also be used for the detection of fetal alleles 
in maternal blood. COLD-PCR was originally applied to the detection of tumour-
associated mutations and the first application to NIPD has been recently 
described by (Galbiati et al., 2011).  
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Our current research is investigating methods to enrich the percentage of 
cffDNA present in maternal plasma so that conditions, such as trisomy 21, could 
be assessed using sensitive techniques such as digital PCR. Relying on the 
size difference between fetal fragment (300 bp) and maternal fragments (>500 
bp), our experiments are aiming to exploit this difference to enrich cffDNA from 
maternal plasma samples. By lowering the denaturation temperature in a PCR 
reaction, we aim to specifically melt the cffDNA and not the maternal DNA, 
hence amplify certain regions of the genome from the specific cffDNA pool, 
without contamination from maternal DNA. Thus by selecting diagnostic regions 
of certain genes such as short tandem repeats (STR), fetal DNA can be 
amplified selectively and be used diagnostically using conventional molecular 
testing such as real time PCR (RT-PCR). A common molecular technique for 
the amplification and detection of trisomy has focused on the use of the 
polymorphic STRs. The majority of DNA markers with STR consist of length 
polymorphisms of di-, tri- or tetranucleotide repeats. It was proposed that STR 
polymorphism could be applied to detect aneuploidies (Liou et al., 2004). 
D21S1890 is one of various polymorphic DNA markers located on chromosome 
21 that contains a STR. Cytosine, adenine (CA) repeat was chosen as the most 
useful STR to focus on in this study due to the high variable number of repeats 
which are non-functional and therefore selectively neutral (Mansfield, 1993). 
However studies have identified that PCR amplification of dinucleotide repeat 
polymorphism are difficult to interpret due to the stuttering bands (Kalaitsidaki et 
al., 1992). 
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1.2 Research aims and objectives 
This project aimed to develop methods for enrichment of free fetal DNA in 
maternal plasma for NIPD purposes. The objectives were as follows: 
 To develop a method for the enrichment of fetal DNA in maternal plasma 
through COLD-PCR. Reducing the temperature of denaturation (Td) 
allows fetal DNA targets to be melted but not the maternal free DNA, due 
to the size difference. Thus optimization of Td by COLD-PCR is to 
determine the precise temperature at which fetal fragment DNA being 
selectively amplified but not maternal DNA fragment.  
 To run different genomic DNA samples on end-point PCR for fragment 
analysis to determine maternal DNA in preparation for spiking 
experiments using capillary electrophoresis. 
 For the project, we could not use clinically-derived cffDNA and thus we 
used a spike experiment where we created a mixture of 5-10% of 
artificial cffDNA in a pool of 95-90% of maternal circulating DNA. This 
was used to imitate the cffDNA in a background of maternal DNA during 
early and late pregnancy. Therefore spiking experiment would be 
performed using fake fetal DNA fragment and fake maternal DNA, at the 
same time using same samples on the end-point PCR with FAM labelled 
primers using capillary electrophoresis for fragment analysis. This would 
be a step toward developing a reliable technique to identify cffDNA in 
maternal plasma. It is hoped that we would have a new rapid, cheap and 
safer choice for the millions of pregnant women worldwide that are 
considering prenatal diagnosis each year.  
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1.3  Literature review: 
Prenatal diagnosis of fetal chromosomal abnormalities represents a major step 
in pregnancy management, allowing stepwise planning and co-ordinated care 
during delivery and the neonatal period. It is mainly performed for detection of 
fetal genetic and chromosomal abnormalities. 
Trisomy 21 is one of the main indications for prenatal diagnosis; it is also the 
most common cause of mental retardation and has an incidence of about 1:700 
to 1:800 live births (Driscoll & Gross, 2009). The condition is associated with 
intellectual impairments, severe learning difficulties and excess mortality caused 
by long term health problems such as heart disease, leukaemia and thyroid 
dysfunction. It results from the presence of three copies of human chromosome 
21. The presence of the extra copy of chromosome 21 causes the physical and 
mental abnormalities characteristic of trisomy 21. Physically, babies with 
trisomy 21 tend to have certain features: poor Moro reflex, excess skin fold on 
the back of neck (in neonate), single crease in the palm of hand (simian 
crease). Other phenotypical features are flat nasal bridge, small mouth, 
protruded tongue and low-set ear. The condition is either due to nondisjunction 
(94% of cases), translocation (3.5% of cases) or mosaicism (2.5% of cases) 
(Chiu and Lo, 2011, Roizen and Patterson, 2003). For the common non-
disjunction type of trisomy 21, the incidence varies markedly with maternal age 
at the time of conception. At a maternal age of 20 years the risk is 
approximately 1:1450, while at 30 years of age the risk is 1:940 and it can reach 
as high as 1:85 by the age of 40 (Morris et al., 2003).  
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1.3.1 Prenatal screening tests 
Screening for trisomy 21 should be offered to all pregnant women; it is 
suggested to be performed by the end of the first trimester (13 weeks) (NICE, 
2010). Women are offered a screening test to determine whether an invasive 
diagnostic test (amniocentesis or CVS) is required for the definitive diagnosis. 
The screening test does not determine the presence of a chromosome 
abnormality per se; it only identifies high risk pregnancies (Graaf et al., 2002).  
First trimester screening test includes maternal serum biochemical screening 
and ultrasound measurement of the nuchal translucency. 
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1.3.2 Maternal serum biochemical screening 
Maternal serum biochemical screening includes biochemical measurement of 
free beta-human chorionic gonadotrophin (β-hCG) and pregnancy associated 
plasma protein A (PAPP-A) (NICE, 2010). They maximize the detection of 
trisomy 21 during the first trimester; the detection rate is around 90-95% of 
pregnancies affected by trisomy 21, at a false positive rate of 5% (Macri and 
Spencer., 1996). The performance is better at 9 to 10 weeks than at 13 weeks 
because the difference in PAPP-A between trisomic and euploid pregnancies is 
greater in earlier gestation (Kagan et al., 2008a, Wright et al., 2010). However 
these screening tests detect phenotypic features instead of genetic pathology 
and they must be conducted within a strict gestational age window (11-14 
weeks) (Malone et al., 2005). Risk can be assessed by several factors, 
including elevated or depressed serum levels of these biomarkers, as well as 
maternal age (Bhide and Thilaganathan, 2004).  
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1.3.3 Ultrasonography (NT)  
A nuchal translucency scan is a screening test which measures the fluid filled 
area at the back of neck between 11 weeks 0 day and 13 weeks 6 days of 
pregnancy, the measurements include only the skin fold from the outer edge of 
the occipital bone to the outer skin edge of the baby. Antenatal screening 
advice that if the measurement of fluid is greater than 3.5 mm, women should 
be referred for chromosomal testing. However false positive rates are high (5%) 
plus most fetal defects are caused by abnormal genetic make-up (chromosomal 
number, morphology and gene defect) and as such many of them cannot be 
detected via ultrasound scan (Huang et al., 2011). 
There are no significant association between fetal NT and maternal serum free 
β-hCG or PAPP-A in either trisomy 21 or euploid pregnancies, and therefore the 
ultrasonographic and biochemical markers can be combined to provide more 
effective screening than either method individually (Spencer et al., 1999). In 
addition to NT, other highly sensitive and specific first-trimester sonographic 
markers of trisomy 21 are absence of nasal bone, increased impedance to flow 
in the ductus venous and tricuspid regurgitation (Nicolaides, 2011). 
Assessment of each of these ultrasound markers can be incorporated into first 
trimester combined screening by fetal NT and serum free β-hCG and PAPP-A, 
resulting in improvement of the performance of screening with an increase in 
detection rate to 96% and a decrease in false positive rate to 2.5 % (Kagan et 
al., 2009). On the other hand, it has been estimated that the second trimester 
scan can improve the detection rate of trisomy 21 achieved by first trimester 
combined screening (Krantz et al., 2007). 
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1.3.4 Invasive prenatal tests 
An abnormal screening result means high risk (cut-off of 1 in 150) and suggests 
the need for more invasive procedures such as CVS and amniocentesis (Avent 
et al., 2009, Bhide and Thilaganathan, 2004). Additionally, women with a history 
of previous premature babies or babies with birth defects especially genetic 
problems or a family history of a chromosomal disorder, are usually offered 
invasive diagnostic tests (Graaf et al., 2002). 
1.3.5 Chorionic villus sampling 
CVS is used most frequently to identify chromosomal problems, such as trisomy 
21. The main advantage of CVS over amniocentesis is that the procedure can 
be performed much earlier in pregnancy i.e. before 14th gestational week, rather 
than 16 to 18 weeks. CVS involves removing a tiny piece of tissue from 
placenta. Under ultrasound guidance, the tissue is obtained either with a needle 
through abdomen or a catheter inserted through the cervix. The tissue is then 
cultured and a karyotype analysis is performed (Huang et al., 2011). 
1.3.6 Amniocentesis 
Amniocentesis is typically performed after the 15th week of gestation. Also 
under ultrasound guidance, a needle is inserted through the abdomen to 
remove a small amount of amniotic fluid. Karyotype analysis will then be 
completed.  
Invasive procedures such as amniocentesis from which the full karyotype is 
usually determined using cultured cells, the two week period needed for 
cultivation and subsequent analysis has proven to be associated with 
considerable parental anxiety and medical problem in those situations requiring 
therapeutic intervention. In order to overcome these problems, a more rapid 
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method for prenatal diagnosis of fetal chromosomal aneuploidy needed to be 
developed. A multi-colour Fluorescence in situ hybridization technique (FISH) 
commercially introduced for uncultured cells, although this method was reliable 
and has proven in large scales studies to be very accurate, it is time and labour-
intensive procedure. Moreover this method requires intact cells, as it can only 
be used on fresh or specially stored samples (Zimmermann et al., 2006, 
Thilaganathan et al., 2000). 
Amniocentesis and CVS are both associated with a risk of miscarriage about 1-
2% as mentioned before and of course added discomfort and stress to mother 
(Mujezinovic and Alfirevic, 2008). Other risks that may associate with 
amniocentesis are introduction of pathogens into the amniotic sac from needle, 
and also possibly preterm labour and delivery. 
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1.3.7 Non-invasive prenatal diagnosis 
Performing prenatal diagnosis non-invasively would be the most promising 
approach for prenatal diagnosis. In order to perform NIPD, a source of fetal 
genetic material that could be sampled without harm to fetus would be needed. 
Many researchers in non-invasive prenatal testing have focused on the isolation 
and analysis of both fetal nucleated cells and cffDNA that have entered into the 
maternal circulation. 
1.3.8 Free fetal cells in maternal circulation  
In 1893 the presence of fetal cells in maternal circulation was documented for 
the first time when multinucleated syncytial trophoblasts were found in the lung 
tissue of pregnant women who died from pre-eclampsia (Lapaire et al., 2007). 
Intact fetal cells, compared to cffDNA have the advantage of retaining complete 
fetal genetic information in the nucleus and cytoplasm that can provide 
information in complex genetic diagnosis (Bhide and Thilaganathan, 2004, 
Graaf et al., 2002). The presence of fetal cells in maternal blood in normal 
pregnancies has been estimated at one to two cells per ml (Reading et al., 
1995). Similar results have been reported by other investigators (Cheung et al., 
1996, Bianchi et al., 1997). A considerable challenge for the researchers in this 
field is to enrich or isolate these rare fetal cells, either for cytogenetic analysis 
by FISH or for analysis of fetal cell DNA by other molecular techniques (Bianchi 
and Hanson, 2006). 
Various fetal cell types found in maternal blood have been explored as potential 
candidates for enrichment and subsequent analysis, including fetal 
trophoblasts, leukocytes and nucleated erythrocytes. Trophoblast enrichment is 
hindered not only by limited availability of antibodies specific to placental 
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antigens, but also by multinucleated morphology (Schueler et al., 2001). 
Leukocytes may persist from previous pregnancies, and isolation strategies are 
also limited by the lack of availability of unique cell markers (Ciaranfi et al., 
1977). Nucleated red blood cells (NRBC) have the advantage of a relatively 
short half-life of 25-35 days; thus, cells of fetal origin are unlikely to persist from 
previous pregnancies. NRBC are also relatively abundant in first trimester 
blood, with unique cell morphology and complete chromosomal complement 
(Bianchi et al., 1990). However, a growing concern has been expressed that 
only a small proportion of the recovered NRBC are actually of fetal origin. 
Moreover, many of these cells are undergoing normal physiological apoptosis, 
and therefore not surprisingly giving rise to unstable or fragmented DNA that is 
not suitable for NIPD (Hristoskova et al., 2001).  
Bianchi et al. (2002) and Babochkina et al. (2005) demonstrated that the 
detection of fetal trisomy from these fetal nucleated erythrocyte cells is difficult; 
possibly due to the fact that the chromosomes in these cells disintegrate some 
time before the nucleus is eliminated from the cell, making FISH analysis of 
samples from maternal circulation unreliable. Therefore because these cells are 
extremely rare and/or may persist for years after prior pregnancies, cffDNA, 
which is more plentiful in the maternal circulation and unique to the current 
pregnancy, may have greater potential for use in prenatal diagnosis. 
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1.3.9 cffDNA in maternal plasma 
Between the 1970s and 1990s, a group of researchers were studying the 
possibility of finding cell free DNA in the plasma of human subjects. One 
particularly interesting line of research was the detection of tumour derived DNA 
in the plasma of women suffering from a variety of cancers. Hence, tumour 
associated oncogene mutations have been detected in the plasma DNA of 
women with cancer (Chen et al., 1996, Nawroz et al., 1996). Inspired by such 
work, Lo et al. hypothesized in 1997 that a fetus might also release its DNA in 
cell-free form into the plasma of its mother. This discovery has opened up new 
possibilities for NIPD. 
The presence cffDNA in maternal plasma was first discovered through the 
detection of Y-chromosome specific sequence in the plasma of women who 
were carrying a male fetus (Lo et al., 1997). The presence of cffDNA in 
maternal plasma is regarded as a major source of fetal genetic material. It 
constitutes about 3-6% of total free DNA, around 3% in early pregnancy and 
rises to 6% in late pregnancy (Lo et al., 1998) but the level is high in cases of 
multiple pregnancies, placental complications, as well as pre-eclampsia (Lo and 
Chiu, 2008, Hahn and Chitty, 2008). Pregnancies with trisomy 21 exhibit 1.7 
fold higher levels of maternal serum cffDNA than controls and also the levels 
increase in trisomy 13 pregnancies but not in trisomy 18 pregnancies (Lo et al., 
1999). cffDNA has been detected in maternal plasma as early as the fourth 
week of gestation (Alberry and Soothill, 2008). In contrast to nucleated fetal 
cells, cffDNA has been showed to be cleared from maternal circulation 
extremely rapidly and it has a short half-life of only 16-28 minute (Rijnders et al., 
2004). In one clinical condition, which is maternal liver disease, significant levels 
of fetal DNA remain in circulation even after delivery (Avent et al., 2009). The 
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majority of cffDNA exists in small fragments that are less than 300 bp, whereas 
maternal DNA is more than 500 bp (Chan et al., 2004). 
This discovery opened up a new field for NIPD, many studies stated that they 
did not observe presence of cffDNA in the blood from non-pregnant women 
whom had experienced previous pregnancies (Rijnders et al., 2004). Those 
results were also confirmed by a study of Bianchi et al. (2002) when they 
observed that there is no SRY gene in the sera of women carrying female 
fetuse with a history of previous male infant. However another study reported 
persistence of fetal DNA several years after delivery (Invernizzi et al., 2002). 
The main hypothesis to explain discordant results of this study is that there may 
have been a potential contaminant or error in the preparation of samples and 
measurements plus the use of improper statistical analysis (Mazouni et al., 
2007). 
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1.3.10 Sources of cffDNA 
Contrary to popular belief that the placenta forms an impermeable barrier 
between mother and child, there is bidirectional traffic between the fetus and 
mother during pregnancy. Multiple studies have shown that both intact fetal 
cells and cffDNA cross the placenta and circulate in the maternal blood stream. 
Potential sources of cffDNA include the fetal nucleated red blood cells which 
undergo apoptosis in the maternal circulation but the most likely source of origin 
is the placenta (Alberry et al., 2007). 
Both serum and plasma can be used as sources for cffDNA but the fractional 
concentration of cffDNA in maternal serum has been found to be lower than that 
in maternal plasma. This is possibly due to liberation of DNA from maternal 
blood cells during the clotting process (Lo, 2000). 
 
 
 
 
 
 
 
 
17 
 
1.3.11 Limitations (problems) associated with detecting 
cffDNA in the maternal circulation 
 
 cffDNA is usually detected using a Y-chromosome gene (SRY), which is not 
present in the maternal genome, and such assays can be used only in 
approximately 50% of pregnancies in which the fetus is male (Alberry and 
Soothill, 2008). 
 The concentration of cffDNA is relatively low. 
 Total amount of cffDNA varies between individuals (Wright and Burton, 
2009). 
 The fetus inherits half of its genome from the mother (Wright and Burton, 
2009). 
 The size fraction of fetal DNA (300 bp) extracted from maternal blood is 
smaller than maternal DNA (>500 bp)     
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1.4 Applications of cffDNA 
1.4.1 Fetal rhesus RhD genotyping 
Presence of cffDNA has enabled NIPD of paternally inherited alleles that are 
absent in maternal genome. It is of clinical relevance to determine the fetal RHD 
status prenatally because RHD positive fetuses from RHD negative mothers are 
at a high risk of haemolytic disease of the fetus and newborn (HDFN). The 
screening tests are based on DNA extraction and RT-PCR amplification to 
detect cffDNA in maternal plasma. The presence of the RHD gene sequence in 
the plasma of a pregnant RHD negative woman suggests an RHD-positive 
fetus. Many clinical centres have already established NIPD techniques for RHD 
genotyping (UK, Netherlands and France) (Chiu and Lo, 2011). 
1.4.2 Fetal sex determination  
Fetal sex determination is used to identify if there is a risk of an X- linked 
disease, through detection of sequence present on Y chromosome in plasma of 
pregnant women carrying male fetus (Finning and Chitty, 2008). This is used in 
X-linked disorders, for example, carrier mothers of serious X-linked conditions 
like Duchenne muscular dystrophy and Hunter disease (autosomal recessive 
disorder which primarily affects males), which confer significant morbidity and 
mortality. Therefore, genetic prenatal diagnosis for women carrying male 
fetuses is required. Gender determination using cffDNA appears to be reliable 
from as early as 7 weeks of gestation (Scheffer et al., 2010); this allows women 
who need invasive procedures to have a CVS at 11 weeks, with knowledge that 
they are not unnecessarily putting a pregnancy at risk. Furthermore early 
determination of fetal gender is of use in the clinical management of fetuses at 
risk of congenital adrenal hyperplasia (CAH), which is a group of genetic 
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disorders that are inherited in an autosomal recessive fashion and result from 
an over production of adrenal androgen. Excessive production of androgen has 
no effect on male external genitalia but varying degrees of virilisation occur in 
affected female fetuses subsequent to the exposure to high levels of 
androgens. Virilisation starts as early as 8 weeks of gestation, but 
administration of dexamethasone to the mother can prevent virilisation by 
suppressing hypothalamic-pituitary-adrenal axis (Avent and Chitty, 2006). Male 
pregnancies will not need steroid therapy, while female pregnancies could have 
steroid prophylaxis for a short period of time prior to CVS at 11 weeks. 
Maximum effect of dexamethasone starts at the sixth week of gestation. NIPD 
will allow determination of fetal sex early on in pregnancy, hence allowing 
dexamethasone treatment to start early and therefore achieving maximum 
effect.  
 
 
 
 
 
 
 
  
20 
 
1.4.3 Single gene disorder 
Currently available techniques are unsuitable for diagnosis of X-linked and 
recessive disorders, as the fetal genes inherited from the mother are swamped 
by the excess of the mother’s own DNA. In recessively inherited conditions, 
such as cystic fibrosis or thalassemia, if the parents carry different mutations 
then exclusion of paternal allele from the maternal plasma indicates that the 
fetus would be unaffected but, if the paternal allele is present, an invasive test is 
required to determine whether the fetus has inherited the abnormal maternal 
allele as well. The possibility of increasing scope for NIPD of single gene 
disorders to include recessive disorders or conditions inherited maternally, was 
demonstrated by Lo and Chiu (2008) when they used digital PCR to detect 
small differences in the levels of the mutant and wild type alleles of disease 
causing genes and to determine whether they were balanced or unbalanced 
and the fetus thus unaffected or affected. Recently a study by Barrett et al. 
(2012) has shown the use of digital PCR for NIPD of sickle cell anaemia. 
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1.4.4 NIPD for chromosomal aneuploidies  
NIPD using cffDNA for chromosomal aneuploidies like trisomy 21 has been 
more difficult because of the high maternal free DNA background. Any method 
that can increase the relative percentage of cffDNA in the sample would make it 
easier to distinguish fetal from maternal DNA and hence detect an abnormal 
concentration of a particular chromosome. 
Gene dosage assessment can be obtained with quantitative PCR, which is 
possible due to the high polymorphisms of STRs. Specific chromosome 
markers for chromosome 21 identify two peaks of fluorescent activity with a 
ratio of 1:1, however trisomic samples will produce either trisomic triallelic (three 
peaks; ratio 1:1:1) or trisomic diallelic (two peaks; ratio; 1:2/ 2:1) results 
(Cirigliano et al., 1999). Zimmermann et al. (2002) identified that through DNA 
quantification of a chromosome 21 locus and a reference locus identified a 1.5 
fold increase in chromosome 21 DNA sequences, however because a 2-fold 
difference in DNA template concentrations only constitutes one Ct, conventional 
RT-PCR assays have shown to be limited to a 1.5 fold discrimination difference. 
Digital PCR is an alternative strategy that can detect overrepresentation of 
chromosome 21 with respect to a reference chromosome, with a finer degree of 
quantitative discrimination (Lo et al., 2007a). 
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1.5 Methods to enrich cffDNA  
Currently, several assay procedures are developed in order to enrich and 
enhance the fractional concentration of cffDNA or just to distinguish the cffDNA 
in maternal blood samples. One point of differentiation between cffDNA and cell 
free maternal DNA is that the former has a shorter size distribution (Li et al., 
2004a). Based on this observation, researchers tried to apply a method of size 
fractionation with the aid of various kits and columns that rely on the inability of 
large molecular weight DNA to pass through or by retention of low molecular 
weight DNA in a gel or column (Legler et al., 2007). Main disadvantage of these 
approaches are: the currently used electrophoretic method is labour intensive 
and probably prone to contamination. It is unknown if the provided DNA 
enrichment is satisfactory enough for the prenatal diagnosis of chromosomal 
aneuploidies (Lo and Chiu, 2008). 
Dhallan et al. (2004) reported another approach for cffDNA enrichment in 
maternal circulation. They proposed that through fixation of maternal nucleated 
blood cells and the use of formaldehyde, the dilution of fetal DNA could be 
avoided in maternal plasma. They went on to demonstrate the utility of this 
approach for NIPD of trisomy 21. There are two speculations about the role of 
formaldehyde in increased yield of fetal DNA: a) prevention of maternal cell lysis 
and subsequent reduction of amount of cell free maternal DNA, b) prevention of 
the degradation of cffDNA by its nuclease inhibitory effect. However 
Chinnapapagari et al. (2005) and  Chung et al. (2005), demonstrated that the 
formaldehyde addition did not yield a dramatic increase in fetal DNA 
concentration as previously reported by Dhallan. A possible reason for this 
discrepancy is that the sample processing time differs between the studies and 
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it is known that the amount of time spent in the tube affects the concentration of 
total cell free DNA. Zhang et al. (2008) proposed that the formaldehyde addition 
will offer a beneficial effect if there is a delay of > 6 hours in sample processing 
as they demonstrated no maternal blood lysis or released extra maternal free 
DNA in to plasma within the first six hours. 
Bischoff (2011) demonstrated that cffDNA is resistant to degradation by DNase, 
supporting the hypothesis that cffDNA is packaged in membranous bound 
vesicles that are formed as a result of apoptosis. They described a novel two 
stage method for enrichment of fetal fragments. The first stage involves 
treatment of total maternal plasma with DNase. Given that fetal fragments are 
more stable and likely packaged by membranous bound apoptotic bodies, they 
hypothesized DNase treatment would deplete the unpackaged maternally 
derived sequence. The second stage involves a modified whole genome 
amplification (WGA) protocol designed to amplify smaller fetal fragments. 
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1.6 Methods to detect fetal aneuploidy by NIPD 
 
1.6.1 RNA single nucleotide polymorphism allelic ratio 
 
Allelic ratio approach is regarded as the most promising single marker approach 
for NIPD of trisomy 21 (Lo et al., 2007b). To achieve diagnosis of fetal 
chromosomal aneuploidy from maternal plasma, it would be reasonable to 
target nucleic acid molecules, which were fetal specific (free from maternal 
background interference) and then to derive chromosome dosage information 
from such molecules (Ferguson, 2003). To provide chromosomal dosage 
information the circulating placental mRNA has to be transcribed from 
chromosome of interest. When SNP is transcribed the fetus with trisomy 21 will 
have an extra copy of the gene. The gene is then expressed in the placental 
tissue and the ratio of the two RNA alleles in the trisomy 21 placenta will differ 
from normal placenta when the transcripts are released in to the maternal 
circulation. The difference in allelic ratio is reflected in the abundance of the 
transcripts, that is the level of circulating placental RNA will be greater in 
trisomy 21 samples (Figure 1). This method is also applicable to the prenatal 
diagnosis of other fetal chromosomal aneuploidies like trisomy 18 and 13. 
However the dependence on genetic polymorphism limits the use of these 
approaches to heterozygous fetuses. 
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Figure 1: The RNA-SNP allelic ratio method of identifying the difference between 
normal and DS fetuses who are heterozygous at the SNP locus of PLAC4, which is 
transcribed by chromosome 21 and expressed from the placenta. PCR amplification 
was used to determine the ratio of SNPs in PLAC4. As the ratio of two alleles in a 
heterozygous euploid fetus would be 1:1 whereas in a trisomic fetus the ratio would be 
either 1:2 or 2:1. Using maternal plasma this ratio could be determined and the number 
of copies of chromosome 21 could be identified noninvasively. (Lo et al., 2007c) Nature 
Med. 13: 218-223 
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1.7 Single molecule counting methods 
The urgent need for the widespread application of NIPD for the detection of 
trisomy 21 has created strong interest in rapid and accurate single molecule 
counting methods (digital PCR and next generation sequencing). 
Single molecule counting methods could be used in routine clinical diagnosis; 
these methods will be polymorphism independent, and will detect trisomy 21 
cases based on the presence per se of an elevated amount of chromosome 21 
sequences in maternal blood. The main disadvantage of these approaches is 
that they require the counting of an extremely large number of molecules for 
markers that are not fetal-specific, and their use demands expensive 
equipment, reagents, and in addition, complex bioinformatics methods.   
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1.7.1 Digital PCR 
Recent reports have indicated that digital PCR, a method that was initially 
applied for determination of the allelic frequencies of oncogenic alterations in 
samples from patients with cancer, could be a valuable new tool in NIPD of 
trisomy 21 (Zimmermann et al., 2008). Digital PCR is a highly sensitive 
technique that uses dilutions to isolate single template DNA molecules to be 
amplified in order to detect very small differences in chromosome ratios. In this 
method fetal derived DNA is not specifically distinguished from maternal DNA 
instead the technique provides a measure of total (fetal and maternal) dosage 
of particular chromosome relative to another reference chromosome. A 
significant barrier for using digital PCR is the small fraction of cffDNA in 
maternal plasma, so this technique requires prior enrichment of cffDNA to 
achieve high accuracy. The analytical precision of digital PCR is superior to that 
of RT-PCR because template molecule quantification does not rely on response 
relationships between reporter dye and nucleic acid concentration.  
To test whether digital PCR is precise enough to detect fetal chromosomal 
aneuploidies in maternal plasma, Lo et al. (2007a) assessed first whether digital 
PCR could measure the allelic ratio of PLAC4 mRNA in maternal plasma, 
thereby distinguishing trisomy 21 from euploid fetuses. They refer to this as the 
digital RNA SNP method. Then they evaluate whether the increased precision 
of digital PCR would allow the detection of fetal chromosomal aneuploidies 
without depending on genetic polymorphisms, and they referred to this 
approach as digital relative chromosome dosage (RCD) analysis.  
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1.7.2 Next generation sequencing  
The principle behind shotgun sequencing is to sequence millions of short DNA 
fragments at the same time. The numbers of sequences from different 
chromosomes are then compared. If a certain sequence is slightly over-
represented this may indicate aneuploidy or chromosomal imbalances. The 
main advantage is that it is polymorphism-independent and it could be used in 
all pregnancies. While the disadvantages are that the approach is prohibitively 
expensive, slow and requires large amount of data processing and 
interpretation. Fan et al. (2008), Chiu et al. (2010) and (Chen et al., 2011) 
reported the successful use of this method for the detection of trisomy 21 at 
gestational ages as early as 14th week. Nevertheless, all these techniques are 
still new and more clinical trials need to be conducted in order to assess their 
clinical effectiveness as a substitute for traditional invasive diagnostic testing. 
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1.8 Ethics  
Prior to NIPD, prenatal testing was already associated with high termination 
rates. But unlike these prior tests, NIPD provides more than an estimated 
likelihood that a fetus will be affected by a certain condition and can be 
performed from the middle of the first trimester of the pregnancy. It is essential 
to realize that there are significant ethical issues that are associated with NIPD. 
Fetal sex determination as early as seven weeks of pregnancy (using NIPD) 
carries a number of socio-ethical implications, such as the promoting the 
selective termination of fetuses according to gender (Marteau and Chitty, 2006). 
Another issue with NIPD for fetal sex determination is that women might seek 
prenatal diagnosis to include paternity testing.  
An additional concern deals with ensuring that women retain their right to 
informed permission for testing. The worry is that with the risk of miscarriage 
removed, health care providers may fail to adequately inform the patients of the 
remaining implication of test outcomes, including learning prior to birth that they 
are pregnant with a child affected with a genetic disease, and thus patients may 
be faced with serious decisions that they were not prepared for. Increasing 
terminations of pregnancies, options for regulation, and non-medical uses such 
as sex selection, are also raised as potential ethical concerns (van den Heuvel 
et al., 2008). A serious disadvantage of early NIPD is that it may increase the 
burden of choice for women, since abnormal fetuses will be identified that would 
have miscarried spontaneously later in pregnancy (Wright and Burton, 2009). 
Prenatal diagnosis will become safer for many women by removing the risks 
associated with invasive tests. This may in turn compromise informed decision 
making since, by removing the need to discuss the miscarriage risk, the 
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decision maker may fail to adequately consider the remaining implications of 
test outcomes (van den Heuvel et al., 2008). Excellent communication with 
women and health professionals is essential to understanding the implications 
of the simple, safe blood tests that they will be offered to detect trisomy 21 as 
well as other conditions. 
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2 Chapter Two: Materials and methods 
2.1 Sample collection and processing 
In this study, female genomic DNA (G1521) (Promega, Southampton) was used 
as a template. Primers for amplification as shown in Appendix A were designed 
by Alice Bruson (a visiting PhD student from Universita delgi di Padova, Italy) 
using the Primer3 software (http://fodo.wi.mit.edu/primer3). Following primer 
design the sequences were subsequently BLASTed to ensure primer specificity 
for the chromosome of interest using Primer-BLAST software. The internal and 
external primers (Eurofins MWG Operon) (www.eurofinsdns.com, Ebersberg) 
used in this study are shown in Table 1. The designed probe (Eurofins MWG 
Operon) had an attached 5’FAM reporter label and a black hole quencher 1 
(BHQ1) quencher dye attached at the 3’ end. 
The TaqMan Probe (Applied Biosystems) is designed as a high-energy dye 
termed a Reporter at the 5’ end, and a low-energy molecule termed a Quencher 
at the 3’ end. When this probe is intact and excited by a light source, the 
reporter dye’s emission would be suppressed by the Quencher dye as a result 
of close proximity of the dyes. When the probe is cleaved by the 5’ nuclease 
activity of the enzyme, the distance between the Reporter and Quencher 
increases, causing the transfer of energy to stop. The fluorescent emission of 
reporter increases and the quencher decreases.   
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All primers and probe were HPLC (high performance liquid chromatography) 
purified. The oligonucleotide synthesis report provided with the primers 
contained other important information including the calculated annealing 
temperature for each primer (see Table 1). The chosen fragment on 
chromosome 21 contains a CA repeat STR identified as D21S1890.  
Genomic DNA for fragment analysis (to act as fake maternal DNA) was 
extracted from buffy coat; twenty four genomic DNA samples were used to 
provide various DNA templates. These samples were collected from random 
donors from National Health Service Blood and Transplant (NHSBT) (Filton, 
Bristol, UK). The DNA was extracted using QIAamp DNA blood mini kit (Qiagen 
Ltd, UK) by personnel in Neil Avent’s Laboratory, Plymouth University.  
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Table 1: The primers and probe sequences for D21S1890. 
Oligo  name Sequence (5’ – 3’ ) GC- 
Content 
Tm (°C) 
D21S1890 
Internal 
Forward 
TCGCCCGAGGGTCTGA 68.8%       56.9ºC 
D21S1890 
Internal 
Reverse 
AAACCAACTGACTCCCAAACAAC 43.5%       58.9ºC 
D21S1890 
Internal 
Forward  
TCGCCCGAGGGTCTGA 
 
5’labelled with FAM 
68.8%       56.9ºC 
D21S1890 
External 
Forward 
GGAGAAACGAGGATGAGCTTC 52.4%       59.8ºC 
D21S1890 
External 
Reverse 
TATTCCCCCGTATTCTTGGT 45%       55.3ºC 
D21S1890 
External 
Forward  
GGAGAAACGAGGATGAGCTTC 
 
5’ labelled with FAM 
52.4%       59.8ºC 
D21S1890 
Probe 
AGATTTCCCAATCGCCA 
 
             5’ labelled with FAM 
3’ labelled with BHQ1 
47.1%       50.4ºC 
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Figure 2: overview of the experimental protocols used. 
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2.2 Methods 
2.3 Polymerase chain reaction (PCR) 
 
2.3.1 PCR to amplify fake fetal DNA fragment 
PCR was used to generate a fake fetal DNA fragment using a Veriti 96-well 
Thermal Cycler (Applied Biosystems, California, USA). The conditions for the 
PCR were as follows; 95 °C for 10 minutes followed by 40 cycles of 95 °C for 30 
seconds, 56 °C for 30 seconds, then 72 °C for 40 seconds, followed by a final 
extension of 72 °C for 7 minutes. This final elongation step ensured that any 
remaining single stranded DNA was fully extended. Female genomic DNA was 
used as template at a final concentration of 4 ng/µl and GenTaq Master Mix was 
used at a final 1x concentration. Unlabelled D21S1890 external forward and 
reverse primers were used both at a final concentration of 200 nM. The PCR 
reaction volume was 50 µl and this was replicated ten times to give a total 
reaction volume of 500 µl. 
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2.3.1.1 Agarose gel electrophoresis 
PCR amplicons were analysed using agarose gel electrophoresis. The samples 
were run on a 2% agarose gel, 1xTAE  (40 mM Tris –acetate 1 mM EDTA and 
acetic acid) (Sigma- Aldrich, UK) and GelRed (Biotium) (1:10.000 dilution) as 
DNA gel stain in order to view the bands of DNA. 10 µl of marker (Ranger 100 
bp DNA ladder, Norgen) was run alongside samples, 100 µl of sample mixed 
with 10 µl of DNA loading buffer [0.36% (w/v) Orange G, 0.47M Tris-HCl (pH 8, 
43% (v/v) glycerol]. Thus total of 110 µl (100 µl DNA sample + 10 µl loading 
dye) was added to each subsequent well. Electrophoresis was performed at 
110 Volts for about 60 minutes. Following the run, the gel was removed and 
placed in the EC3 imaging system (UVP BioImaging System, Cambridge, UK) 
and results were analysed using the Launch Vision WorksLS program (Chemi 
Doc 410). 
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2.3.1.2 DNA gel extraction  
The fragments were excised from the agarose gel using a sharp scalpel and 
then weighed. DNA fragments were extracted and purified according to 
manufacturer’s instructions in the QIAquick gel extraction kit (Qiagen). Briefly, 
three volumes of buffer QG were added to 1 volume of gel. Following a 10 
minute incubation period at 50 °C, one gel volume of isopropanol was added to 
each sample and mixed to increase the yield of DNA fragment. DNA samples 
were added to a QIAquick spin column in a collection tube and following one 
minute of centrifugation the flow through was discarded. Afterward, the sample 
was washed by adding 0.75 ml of buffer PE to the QIAquick column and 
centrifuged for one minute. Flow through was discarded again and re-
centrifuged for an additional minute to remove residual ethanol from column. 
Final step was performed by adding 50 µl of buffer EB to the column and 
centrifuged for one minute (after placing QIAquick column into a clean 1.5 ml 
microcentrifuge tube). Once DNA had been extracted it was quantified using the 
Nano Vue Plus spectrophotometer. 
2.3.1.3 Assessment of DNA quality and quantity 
The NanoVue Plus Spectrophotometer (GE Healthcare, Little Chalfont, UK) was 
used to measure DNA concentration and quality of each sample. The optical 
density was assessed at 260 nm and 280 nm. A DNA quality control threshold 
was set with an A260/A280 ratio of between 1.6 and 1.95. The extracted DNA 
was stored at -20°C. 
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2.3.2 PCR for selection of fake maternal DNA  
PCR was conducted using Veriti 96-Well Thermal Cycler (Applied Biosystems) 
with 5’FAM labelled D21S1890 external forward and non-labelled external 
reverse primers both at a final concentration of 400 nM. Cycling conditions were 
same as (Method 2.4.1) but with thirty five cycles instead of forty. Using 
AmpliTaq Gold (Applied Biosystems) enzyme at a final concentration of 
1.25Unit/reaction, dNTPs 200 µM, MgCl2 2 mM. Purified DNA of twenty four 
different genomic DNA from buffy coat samples were used as templates at a 
final concentration of 4 ng/µl. Twenty six reaction tubes were prepared in total 
containing a 25 µl reaction volume in each: twenty four tubes containing 
template DNA (from buffy coat), one tube contains female genomic DNA, and 
one tube with water as a negative control. 10 µl of PCR products were run out 
on a 2% agarose gel at 100 volts for one hour.  
Thereafter, Dr Michele Kiernan carried out a sequence analysis on 2 µl from the 
remaining PCR samples using ABI Genetic Analyser 3130 (Applied Biosystems, 
Warrington, UK). The information obtained was analysed using Peak ScannerTM 
fragment analysis Software Version 1.0. 
AmpliTaq Gold is a thermostable DNA polymerase designed to improve the 
amplification of templates by lowering the nonspecific background and 
increasing the amplification of required specific products. 
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2.3.3 Performing PCR with internal primers for fake fetal 
and fake maternal DNA fragment 
 
PCR using D21S1890 5’FAM labelled internal forward and non-labelled internal 
reverse primers, both at a final concentration of 400 nM, was carried out using a 
Veriti 96-Well Thermal Cycler (Applied Biosystems). Fake maternal DNA 
(6534H from buffy coat) and fake fetal DNA (from female genomic DNA) were 
used as templates at a final concentration of 4 ng/µl and 0.4 ng/µl respectively, 
and TaqMan Universal PCR Master Mix (Applied Biosystems) at 1x 
concentration. Making up Master Mix to (20 µl/tube) and 5 µl from each 
template plus one tube of water as a negative control. Running program was as 
follows; 50 °C for two minutes, 95 °C for ten minute, 50 °C for one minute 
followed by 45 cycles of  95 °C for fifteen seconds and 56 ºC for one minute.  
Moreover we have used Enhancer with AmpliTaq Gold enzyme. The Master 
Taq Kit contains recombinant Taq DNA polymerase purified from Escherichia 
coli DH1, a 10x Taq Buffer with 15 mM MgCl2, a separate 25 mM Magnesium 
solution, and the special 5xTaqMaster PCR enhancer to help with the 
performance of sensitive and sophisticated PCR applications on difficult 
template DNA.  
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2.3.4 Real-Time PCR (RT-PCR) to find critical 
denaturation temperature of fake fetal DNA 
 
RT-PCR was used to find the critical denaturation temperature using D21S1890 
internal forward and reverse primers, different concentrations of primers and 
probes were used as shown in Table 2. PCR was performed using TaqMan 
Universal PCR Master Mix (Applied Biosystems) at 1x concentration and made 
up to solutions that allowed 20 µl of mastermix solution to be added to each 
reaction. Female genomic DNA and fake fetal DNA were used as templates at a 
final concentration of 4 ng/µl and 0.004 ng/µl respectively. Water was used as a 
negative control, DNA samples were all in triplicate. 5 µl of each template was 
used. The cycle sequence was run on the StepOnePlus RT-PCR (Applied 
Biosystems) as follows: 50 °C for two minute, 95 °C for ten minutes, and 50 °C 
for one minute, followed by 45 cycles of 95 °C for fifteen seconds and 56 °C for 
one minute. Series of RT-PCR runs were conducted altering the denaturation 
temperature for each; they were conducted at (84°C - 83°C - 82°C -81°C-
81.8°C -81.6°C -81.4°C -81.2°C -80°C). The threshold cycle was determined 
using StepOne Software (v2.1) automatically. 
 
Table 2: Primer and probe concentrations for RT-PCR. 
Attempts Primer Mix Probe 
Attempt A 200 nM 100 nM 
Attempt B 300 nM 100 nM 
Attempt C 200 nM 50 nM 
Attempt D 300 nM 50 nM 
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2.3.5 SYBR Green RT-PCR 
SYBR Green dye is the most commonly used dye for non-specific detection. It 
is a double-stranded DNA intercalating dye, that fluoresces once bound to the 
DNA. A pair of specific primers is required to amplify the target with this 
chemistry. The amount of dye incorporated is proportional to the amount of the 
generated target. The inconvenience of this technique is that SYBR Green I will 
bind to any amplified dsDNA. Consequently, primer dimers or unspecific 
products introduce a bias in the quantification. However, it is still possible to 
check out  the specificity of the system by running a melt curve analysis at the 
end of PCR run. The principle is that every product has a different dissociation 
temperature, depending on the size and base composition, so it is still possible 
to check the number of products amplified. 
Instead of using fluorescent probe, 1x SYBR Green mastermix (Applied 
Biosystems) was added to forward and reverse D21S1890 primers both at final 
concentration of 200 nM and made up total mix that allowed 20 µl of master mix 
solution to be added to each reaction. Melt curve analysis was carried out using 
gradient options on StepOnePlus software to run two temperatures at the same 
time one at 95 °C as a positive control and the other at 80 °C (critical 
denaturation temperature). As SYBR Green binds to any double stranded DNA 
the amount of fluorescence indicates the amount of dsDNA present. As the 
DNA is heated to the denaturation temperature the dsDNA melts to single 
stranded DNA and the denaturation temperature is detected by a loss of 
fluorescence, the midpoint of this transition is known as melting temperature of 
the sample and is characteristic of a given DNA sequence. Therefore melt 
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curves are useful for determining the specificity of a PCR reaction, as any 
nonspecific amplification products will have a different melt curve profile than 
the target sequence (Ririe et al., 1997). The templates were 6534H genomic 
DNA (fake maternal DNA) at a final concentration of 4 ng/µl, fake fetal DNA at 
0.4 ng/µl and spike sample (90% fake maternal DNA and 10% fake fetal DNA). 
Plus water as a negative control. Samples were all run in triplicate.  
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2.3.6 PCR for cloning experiment 
PCR using D21S1890 external forward and reverse primers was carried out 
using a Veriti 96-Well Thermal Cycler (Applied Biosystems). The primers were 
used at a final concentration of 200 nM. Fake fetal and fake maternal DNA were 
used as templates at a final concentration of 0.4 ng/µl and 4 ng/µl respectively.  
BioMix Master Mix (Bioline, Ltd UK) was used at 1x final concentration. Thus 
two samples were prepared each with 20 µl of Master Mix, one with 5 µl of fake 
fetal DNA and the other with 5 µl of fake maternal DNA. The Cycle sequence 
was as follows; 95 °C for 10 minutes followed by 40 cycles of 95 °C for 30 
seconds , 56 °C for 30 seconds, then 72 °C for 60 seconds, followed by a final 
extension of  72 °C for 20 minutes. PCR products were cloned into pCR®-4 
TOPO® (InvitrogenTM), using the TOPO TA cloning method according to the 
manufacturer’s protocol (Method 2.8.4).  
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2.4 Whole genome amplification of fake maternal DNA 
(6534H) 
 
REPLI-g UltraFast Mini Kit (Qiagen) was used to amplify genomic DNA (sample 
6534H) according to the manufacturer’s instructions. The method is based on 
Multiple Displacement Amplification (MDA) technology, which carries out 
isothermal genome amplification utilizing a uniquely processive DNA 
polymerase capable of replicating 100 kb without dissociating from the genomic 
DNA template. The sample is lysed and the DNA is denatured by adding 
denaturation buffer. After denaturation has been stopped with addition of 
neutralization buffer, a Master Mix, containing reaction buffer and REPLI-g 
UltraFast DNA Polymerase, was added. The isothermal amplification reaction 
proceeds for one and a half hours at 30 ºC.  
The first step was to prepare Buffer D1 (denaturation buffer) and Buffer N1 
(neutralization buffer), Buffer D1 was made by adding 2.5 µl of reconstituted 
buffer DLB and 7.5 µl of nuclease free water. Buffer N1 was made from 4 µl of 
stop solution and 36 µl of nuclease free water. Then 1 µl of 6534H genomic 
DNA was added into a microcentrifuge tube, 1 µl buffer D1 added to the sample 
and mixed by vortexing and centrifuging briefly and then the sample incubated 
at room temperature for three minutes. After that 2 µl buffer N1 added to the 
sample and vortexed again. Master Mix was made from 15 µl REPLI-g UltraFast 
reaction buffer and 1 µl REPLI-g UltraFast DNA polymerase, the total 16 µl was 
added to 4 µl of denatured DNA and incubated at 30 ºC for one and half hours.  
Heating of sample was required to inactivate REPLI-g UltraFast DNA 
polymerase for that the sample was heated on a hot block of 65 °C for three 
45 
 
minutes. Concentration was calculated from absorbance reading 893.5 ng/µl, 
the A260/A280 ratio was 1.619, and the A260/A230 ratio was 1.742. The 
extracted DNA was stored at -20 °C. 
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2.5 Spike Experiment 
The purpose of spiking experiment was to amplify the fake fetal DNA fragment 
without amplifying genomic DNA. Spike experiments were performed using fake 
fetal fragment (amplified from female genomic DNA, Promega) and fake 
maternal DNA (6534H genomic DNA from buffy coat) with D21S1890 internal 
forward and reverse primers at a final concentration of 200 nM and TaqMan 
probe 100 nM. 
Two RT-PCR reactions were performed one with a denaturation temperature of 
95 °C as a positive control and a second reaction performed with a critical 
denaturation temperature of 80 °C. At the same time as setting up the spiking 
experiment for RT-PCR we have set identical runs for Veriti (endpoint PCR) 
with the final volume of 50 µl per each reaction  (for fragment analysis and 
acrylamide gel), instead of using labelled probe, 5’FAM labelled D21S1890 
internal primer was used at a final concentration of 200 nM. Fake fetal fragment 
and 6534H genomic DNA were used in order to establish standard curve, this 
was carried out by making different dilutions of genomic DNA which was used 
as standard curve at a denaturation temperature of 95 °C (20 ng/µl, 2 ng/µl, 0.2 
ng/µl and 0.02 ng/µl) and different dilutions of fake fetal DNA (2 ng/µl, 0.2 ng/µl, 
0.02 ng/µl and 0.002 ng/µl) were used as standard curve at critical denaturation 
temperature of 80 ºC. Therefore four plates were run at two different 
temperatures using RT-PCR StepOnePlus and endpoint PCR.  
The spike samples were made of mixture of fake fetal and fake maternal DNA in 
two different concentrations; spike A was made of 90% of fake maternal DNA 
and the remaining 10% being fake fetal DNA. Spike B was made of 95% of fake 
maternal DNA and the remaining 5% of fake fetal DNA as shown in Table 3. 
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Genomic A and B were used as templates, genomic A (90% genomic DNA and 
10% water), genomic B (95% genomic DNA and 5% water). Fetal A and B also 
used as templates, fetal A (90% water and 10% fake fetal fragment), fetal B 
(95% water and 5% fake fetal fragment). Water was used as negative control 
(NTC) and each sample was run in triplicate as shown in plate layout (Table 4 
and Table 5). The PCR products with internal D21S1890 FAM labelled forward 
primer (endpoint PCR) were run out on an agarose gel to check product size, 
on an acrylamide gel, and 1-2 µl of remaining PCR product was used for 
fragment analysis on genetic analyser. 
 
 
Table 3: The composition of spike samples. 
Categories Amount of fetal DNA per well Amount of genomic DNA 
per well 
Spike A 10 ng 90 ng 
Spike B 5 ng 95 ng 
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Table 4: The table displays the plate layout of the spike experiment at a critical denaturation temperature (Td) of 95 ºC (as a positive 
control plate). Fake maternal DNA (6534H) at four different dilutions: [S1 (20 ng/µl), S2 (2 ng/µl), S3 (0.2 ng/µl), S4 (0.02 ng/µl)] were 
used as a standard curve (STD). spike A (90% fake maternal DNA + 10% fake fetal DNA), spike B (95% fake maternal DNA + 5% fake 
fetal DNA). Genomic DNA A (fake maternal DNA) = 90% gDNA + 10% water, genomic DNA B = 95% gDNA + 5% water. Fake fetal DNA 
A (FFDNA. A) = 90% water + 10% fetal DNA, fake fetal DNA B= 95% water + 5% fetal DNA. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 6534H 
20ng/µl 
 
STD 
 
6534H 
20ng/µl 
 
STD 
6534H 
20ng/µl 
 
STD 
6534H 
2ng/µl 
 
STD 
6534H 
2ng/µl 
 
STD 
6534H 
2ng/µl 
 
STD 
6534H 
0.2ng/µl 
 
STD 
6534H 
0.2ng/µl 
 
STD 
6534H 
0.2ng/µl 
 
STD 
6534H 
0.02ng/µl 
 
STD 
6534H 
0.02ng/µl 
 
STD 
6534H 
0.02ng/µl 
 
STD 
B Spike. A 
 
90%-10% 
 
Spike. A 
 
90-10% 
 
Spike. A 
 
90%-10% 
 
Spike. B 
 
95%-5% 
Spike. B 
 
95%-5% 
Spike. B 
 
95%-5% 
WATER 
 
NTC 
 
WATER 
 
NTC 
WATER 
 
NTC 
   
C gDNA. A 
 
20 ng/µl 
gDNA. A 
 
20 ng/µl 
gDNA. A 
 
20 ng/µl 
gDNA. B 
 
20 ng/µl 
gDNA. B 
 
20ng/µl 
gDNA. B 
 
20 ng/µl 
      
D FFDNA 
A 
 
2ng/µl 
 
FF DNA  
A 
 
2ng/µl 
 
FFDNA 
A 
 
2ng/µl 
 
FFDNA  
B 
 
2ng/µl 
 
FFDNA 
B 
 
2ng/µl 
 
FFDNA  
B 
 
2ng/µl 
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Table 5: The table displays the plate layout of the spike experiment at a critical Td of 80°C. Fake fetal  DNA at four different dilutions: [S2 
(2 ng/µl), S3 (0.2 ng/µl), S4 (0.02 ng/µl), S5 (0.002 ng/µl)] were used as a standard curve (STD). Spike A (90% fake maternal DNA + 
10% fake fetal DNA), spike B (95% fake maternal DNA + 5% fake fetal DNA). Genomic DNA A (fake maternal DNA) = 90% gDNA + 10% 
water, genomic DNA B = 95% gDNA + 5% water. Fake fetal DNA A (FFDNA. A) = 90% water + 10% fetal DNA, fake fetal DNA B= 95% 
water + 5% fetal DNA. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A FFDNA  
2ng/µl 
 
STD 
 
FFDNA  
2ng/µl 
 
STD 
FFDNA  
2ng/µl 
 
STD 
FFDNA  
0.2ng/µl 
 
STD 
FFDNA  
0.2ng/µl 
 
STD 
FFDNA  
0.2ng/µl 
 
STD 
FFDNA  
0.02ng/µl 
 
STD 
FFDNA  
0.02ng/µl 
 
STD 
FFDNA  
0.02ng/µl 
 
STD 
FFDNA  
0.002ng/µl 
 
STD 
FFDNA  
0.002ng/µl 
 
STD 
FFDNA  
0.002ng/µl 
 
STD 
B Spike. A 
 
90%-10% 
 
Spike. A 
 
90%-10% 
 
Spike. A 
 
90%-10% 
 
Spike.B 
 
95%-5% 
Spike.B 
 
95%-5% 
Spike.B 
 
95%-5% 
WATER 
 
NTC 
WATER 
 
NTC 
WATER 
 
NTC 
   
C gDNA.A 
 
20ng/µl 
gDNA.A 
 
20ng/µl 
gDNA.A 
 
20ng/µl 
gDNA.B 
 
20ng/µl 
gDNA. B 
 
20ng/µl 
gDNA.B 
 
20ng/µl 
      
D FFDNA 
A  
2ng/µl 
 
FFDNA 
A  
2ng/µl 
 
FFDNA 
A  
2ng/µl 
 
FFDNA 
B  
2ng/µl 
 
FFDNA 
B  
2ng/µl 
 
FFDNA 
B  
2ng/µl 
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2.6 Polyacrylamide Gel Electrophoresis 
Non-denaturing polyacrylamide gel electrophoresis was used for separation and 
purification of fragments of double stranded DNA. A mini-PROTEAN TBE 
Precast Gel (10% acrylamide) (Bio-Rad Laboratories) was used. The gel was 
run using a mini PROTEAN Tetra System. Loading dye was made from [12.5 
mM Tris (pH 8), 30% (v/v) glycerol, 0.25% (w/v) bromophenol blue]. 3 µl of 
loading dye was added to 15 µl of PCR product generated from fake maternal 
DNA (samples A and B), fake fetal DNA (samples A and B) and admixes of fake 
maternal and fetal DNA (spike A and spike B) at denaturation temperatures of 
95 ºC and 80 ºC. 18 µl of these samples were added (15 µl PCR sample + 3 µl 
loading dye) to the gel along with 12 µl of marker (Ranger 100bp DNA ladder, 
Norgen). The gel was run in 1x TBE (10XTBE (Bio-Rad laboratories. Tris, Boric 
Acid and EDTA buffer) for two and half hours at sixty volts then transferred to a 
gel tray with 20 ml 1x TBE and 7.5 µl GelRed (Biotium) 1:10.000 dilution as 
DNA gel stain. This was transferred to a gyro-rocker and rocked at room 
temperature for sixty minutes. And then the gel was placed in the EC3 imaging 
system (UVP Bio Imaging System, Cambridge, UK) and results were analysed 
using Launch vision WorksLS program (Chemi Doc 410).  
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2.7 Cloning experiment 
      Experimental outline 
 Preparing Luria Bertani media and agar 
 Producing PCR Product  
 Cleaning of PCR product 
 TOPO® Cloning reaction (mixing PCR product and pCR® 4-TOPO® 
 Transforming into One Shot® Mach 1 TM- T1R Chemically Competent E. 
coli cells 
 Selecting and analysing colonies 
 Performing colony PCR 
 Isolating plasmid DNA 
 Digestion of plasmid DNA 
 Sequencing of plasmids 
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2.7.1 Cleaning of PCR product 
After performing a PCR for cloning reaction (Method 2.4.6), QIAquick Gel 
Extraction Kit (Qiagen) was used for cleaning the DNA from enzymatic 
reactions according to the manufacturer’s instructions. Through adding three 
volumes of Buffer QG and one volume of isopropanol to the PCR reaction, then 
for binding DNA the samples was added to QIAquick column and centrifuged for 
one minute. For washing step, 0.75 ml of Buffer PE was added to QIAquick 
column and centrifuged for one minute. To completely remove residual ethanol 
from the column, the flow-through was discarded and centrifuged for additional 
one minute. Final step was performed by adding 50 µl of Buffer EB to the 
column (after placing QIAquick column into a clean 1.5 ml microcentrifuge tube) 
and the column was centrifuged for one minute. 
Concentrations were calculated from absorbance reading using Nano Vue Plus 
spectrophotometer (GE Healthcare): 
Female genomic DNA: 20.5 ng/µl, the A260/A280 ratio was 1.708, and the 
A260/A230 ratio was 0.061. 
Fake maternal DNA: 20.0 ng/µl with A260/A280 ratio of 1.674, and the 
A260/A230 ratio was 0.325. 
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2.7.2 Luria Bertani Media (LB Media)  
The LB media was prepared by dissolving 10 g of LB broth (Sigma) in 500 ml of 
distilled water. The solution was autoclaved and stored at room temperature 
until required. 
2.7.3  Luria Bertani Agar (LB plates) 
The LB plates were prepared by dissolving 12 g of Bacteriological Agar powder 
(Sigma) in one litre of distilled water. The solution was sterilized by autoclaving 
and cooled to 50 °C prior to the addition of the appropriate antibiotics at the 
required concentration. The selective plates used in this study included 
ampicillin ready-made solution (Sigma) at a concentration of 50-100 µg/ml.   
For making twenty plates of LB agar with ampicillin and X-gal; 300 µl of 
ampicillin were added to 300 ml of LB agar under aseptic condition, and then 
thin layer (5 mm) of LB Agar poured in to each plate (swirl plate in a circular 
motion to distribute agar on bottom completely). 
 For Blue/White Colony Screening 5-bromo -4-chloro-indolyl-β-D-
galactopyranoside (5 mg substrate per tablet) (X-Gal). X-Gal was made from 
dissolving two tablets into 500 µl of Dimethylformamide (DMF); 40 µl of X-Gal 
applied to top of agar, and spread over the entire surface of the plate under 
aseptic condition.  
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2.7.4 Performing the TOPO® cloning Reaction  
The freshly purified PCR Product was cloned into the vector pCR®-4TOPO® 
(Invitrogen). To perform the TOPO Cloning reaction 1 µl of fresh PCR product, 1 
µl of salt solution (1.2 M NaCl, 0.06 M MgCl2), 1 µl of TOPO® vector and 2 µl of 
water were added into microcentrifuge tube mixed gently and incubated for five 
minutes at room temperature.  
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2.7.5 Transformation of DNA into Mach 1 TM- T1R 
competent   E. coli cells 
 
Transformation is the introduction of a plasmid into a competent cell. A 
competent cell is a cell that is chemically treated to allow its membrane to be 
permeated by plasmids. The plasmid will be replicated in the bacteria, which will 
copy the DNA fragment of interest. Often the plasmid carries a gene that can 
make the bacteria resistant to an antibiotic. Only the bacteria that carry the 
plasmid will grow in the presence of that antibiotic.  
After performing TOPO® Cloning reaction, 2 µl from total reaction volume (5 µl) 
was added into a vial of One Shot® Mach 1 TM- T1R Chemically competent E. 
coli cells After 30 minutes incubation on ice, cells were heat shocked for 30 
seconds at 42 °C and then incubated for an hour in S.O.C medium (2% w/v 
Tryptone, 0.5% w/v Yeast Extract, 10 mM NaCl, 2.5 mM, KCl, 10 mM MgCl2, 
10mm MgSO4, 20 mM glucose; provided with the kit) at 37 °C. After the 
incubation, 150 µl was transferred to the centre of an agar plate containing 
appropriate antibiotic, and a sterile spreader was used to spread the solution 
over the entire surface of the plate. The plates were stored at room temperature 
until the liquid had been absorbed, then the plates were inverted and incubated 
overnight at 37 °C.  
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2.7.6 Colony PCR 
PCR was done to analyse positive transformants. Colony PCR was performed 
for female genomic DNA by picking five white colonies from plate and one blue 
colony, each one of these colonies were added to 300 µl of nuclease free water 
and then heated on heat block at 95 °C for five minutes. M13 forward (5’-
GTAAAACGACGGCCAGT-3’) and reverse (5’-AACAGCTATGACATG-3’) 
primers were used at a final concentration of 100 nM. BioMix Master Mix 
(Bioline) was used at 1x final concentration. Therefore six reaction tubes were 
prepared (5 samples of white colony, 1 sample blue colony). The cycle 
sequence was run on the Veriti 96 well thermal cycler (Applied Biosystems) as 
follows; 95 °C for 5 minutes followed by 40 cycles of 94 °C for 30 seconds, 55 
°C for 30 seconds, then 72 °C for 60 seconds. Succeeding the 40 cycles, there 
was a final elongation step at 72 °C for 5 minutes. PCR samples were run out 
using  agarose gel electrophoresis. 
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2.7.7 Isolation of plasmid DNA 
For female genomic DNA sample, five colonies were picked up and grown in 
liquid selective LB medium (5 universal bottles each containing 10 ml of LB 
medium + 100 µl of ampicillin) for 16 hours at 37 °C, with vigorous shaking.  
The plasmids containing the insert had to be isolated from the bacterial cells. 
Therefore plasmid DNA purification was done using (QIAprep spin Miniprep Kit) 
(Qiagen) according to the manufacturer’s instructions. 2 ml overnight culture of 
E. coli in LB medium was transferred to a microcentrifuge tube and centrifuged 
for one minute. The supernatant was discarded; pelleted bacterial cells were 
resuspended in 250 µl buffer P1 and transferred to a microcentrifuge tube. Then 
250 µl of buffer P2 was added and mixed thoroughly by inverting the tube 4-6 
times. 350 µl of buffer N3 was added and mixed immediately, but thoroughly, by 
inverting the tube 4-6 times. After that the mixture was centrifuged for ten 
minutes at 13,000 rpm (17,900xg). The supernatants applied to the QIAprep 
spin column by decanting and centrifuged for sixty seconds. QIAprep spin 
column was washed by adding 0.75 ml of buffer PE and centrifuged for sixty 
seconds. To remove residual wash buffer, flow through was discarded and the 
column centrifuged for an additional one minute. To elute DNA the QIAprep 
column placed in clean 1.5 ml microcentrifuge and 50 µl of buffer EB was added 
to the centre of QIAprep spin column and centrifuged for one minute. Isolated 
plasmids were screened for an insert by digestion with an EcoRl restriction 
enzyme (Promega, Southampton) at 37 °C for one hour.   
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2.7.8 Digestion of plasmid DNA  
Restriction enzymes are enzymes that recognize short DNA sequences. They 
cleave double stranded DNA at specific sites within or adjacent to their 
recognition sequences. Recognition sequence for EcoRI is 5’…GAATT C…3’, 
3’…C TTAA G…5’. One unit is defined as the amount of enzyme required to 
completely digest 1 µg of DNA in one hour at 37 °C in 50 µl assay buffer 
containing Acetylated Bovine Serum Albumin (BSA) added to a final 
concentration of 0.1 mg/ml. Thus 1 µl DNA (after plasmid DNA purification), 1 µl 
of buffer H [1x buffer H supplied with the enzyme has composition of 90 mM 
Tris-HCl (pH 7.5), 50 mM NaCl and 10 mM MgCl2 at 37 °C], 0.25 µl of restriction 
enzyme (three units) and 0.1 µl of BSA was added to 7 µl of nuclease free 
water. The reaction mixture was centrifuged and then incubated at 37 °C for 
one hour. When digestion was completed reaction volume was mixed with 2 µl 
of loading dye [12.5 mM Tris (pH 8), 30% (v/v) glycerol, 0.25% (w/v) 
bromophenol blue] and run on the 10% acrylamide gel for two and half hours at 
sixty volts. And then the gel was placed in the EC3 imaging system (UVP Bio 
Imaging System, Cambridge, UK) and results were analysed using Launch 
vision WorksLS program (Chemi Doc 410). 
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2.7.9 Sequencing  
The plasmid DNA from the starting PCR template of female genomic DNA were 
sent for sequencing by (Eurofins MWG Sequencing) using M13 forward and 
reverse primers. Each sample was diluted to the final concentration of 50 ng/µl 
in minimum volume of 15 µl. 
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3 Chapter Three: Results 
3.1 Amplification of fake fetal DNA fragment 
A PCR was carried out for the amplification of the 229 bp fake fetal DNA 
fragment from female genomic DNA using the D21S1890 external forward and 
reverse primers. This was done by using PCR and electrophoresis followed by 
gel extraction. Figure 3 shows five thick bands fluorescing strongly under UV 
light between 200 bp and 300 bp (expected size 229 bp) according to the DNA 
ladder. The product produced will be referred from here onwards as fake fetal 
DNA fragment. After gel extraction of these bands the fragment DNA recovered 
was quantified using a NanoVue Plus Spectrophotometer. Concentrations were 
calculated from absorbance reading 14.1ng/µl, the A260/A280 ratio was 2.178, 
and the A260/A230 ratio was 0.016. Hence this sample was regarded as fake 
fetal DNA fragment in this study.  
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Figure 3: Agarose gel showing fake fetal DNA fragment amplified by PCR with the 
D21S1890 external forward and reverse primers. M= DNA ladder, lane 1-5 are 
identical, each containing 110 µl (100 µl of PCR product from female gDNA template + 
10 µl of loading buffer). 
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3.2 RT-PCR to find critical denaturation temperature 
 
Fake fetal DNA was used to find critical denaturation temperature, but before 
running fake fetal DNA as a template, different concentrations of primers and 
probe were used for making a mastermix as shown in Table 2 in an attempt to 
find best results from these attempts and then running fake fetal DNA as 
template with chosen conditions to find critical denaturation temperature. 
Results from these attempts are shown in Appendix B. 
COLD-RT PCR was carried out at a denaturation temperature of 78.8 ºC and 
yielded no product from any templates (fake fetal and genomic DNA). This 
temperature was chosen as previous investigation in Neil Avent’s laboratory 
(unpublished data) had suggested this could be the critical denaturation 
temperature of this region (using endpoint PCR). To find the critical 
denaturation temperature the procedure was run multiple times using the same 
templates with the same reaction conditions. Starting from this point (78.8 °C), a 
range of different denaturation temperatures were tried to find the critical 
denaturation temperature (84 °C - 83 °C - 82 °C - 81 °C - 81.8 °C - 81.6 °C -
81.4 °C - 81.2 °C - 80 °C) at which  there would be no amplification of female 
genomic DNA but with the amplification of fake fetal DNA. The first run was 
done using D21S1890 external forward and reverse primers with fake fetal DNA 
and female genomic DNA as templates at a denaturation temperature of 95 °C 
as a positive control. Result from Figure 4 A indicates that both fetal and 
genomic DNA samples were amplified. Mean Ct value of fake fetal DNA and 
female genomic DNA was 11 and 26 respectively at a denaturation temperature 
of 95 °C. Results from other denaturation temperatures, for example 84 °C, 
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showed no amplification of genomic DNA, however fake fetal DNA showed 
amplification with very late Ct value of 31.09 as presented in Figure 3 B. The 
temperature of 80 °C was selected as critical denaturation temperature since 
the aim was to amplify only fake fetal DNA, indicating that this denaturation 
temperature is too low for genomic DNA amplification. Mean Ct value for 
genomic DNA was undetermined at a critical denaturation temperature of 80 °C 
while mean Ct value for fake fetal DNA was 29. No template control (NTC) 
samples (in triplicate) did not show any contamination, indicating no 
amplification of product for all denaturation temperatures (denaturation 
temperature of 95 °C, 80 °C and 84 °C) Results of other denaturation 
temperatures that have been tried are shown in Appendix C1 and C2. 
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Figure 4: RT-PCR amplification plots to determine critical denaturation temperature. A) 
At a Td of 95  C, the mean Ct value was 11 and 26 for fake fetal DNA (ffDNA) 
(0.02ng/µl) and gDNA (20ng/µl) respectively. B) At a Td of 84  C, the mean Ct value 
was 31.09 for ffDNA with undetermined Ct value for gDNA. C) At a critical Td of 80 °C 
the mean Ct value was 29.70 for ffDNA with undetermined Ct value for gDNA. No 
template control (NTC) traces show no amplification indicating that there were no 
contamination at all temperatures. 
A) RT-PCR amplification plot at a Td 
of 95 °C. 
B) RT-PCR amplification plot at a Td 
of 84 °C. 
 
C) RT-PCR amplification plot at a Td 
of 80 °C. 
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3.3 Fragment analysis to find fake maternal DNA 
End point PCR using 5’FAM labelled external forward and non-labelled external 
reverse  primers produced labelled DNA fragment (Method 2.3.2) from twenty 
four different genomic DNA samples (derived from buffy coat). These samples 
were compared with female genomic DNA which fake fetal DNA was produced 
from, in order to find fake maternal DNA for spiking experiment. The CA repeat 
in chromosome 21 marker region varies within the population. For the reason 
that every individual inherits one allele from their mother and one from their 
father, we expected to see two major peaks from each of these samples.  By 
comparing the peaks from the different samples with the female genomic DNA 
we wanted one of these major peaks to match and the other peak to not match. 
Using this principle, we have chosen the sample to act as fake maternal DNA 
for the spiking experiment.  
A portion of the PCR products were initially run for forty five minutes at ninety 
volts across an agarose gel. This was to verify that product had been amplified 
and that it was of the correct size. The gel photo showed that all templates had 
given a good strong band at approximately 229 bp as expected; these results 
are shown in Appendix D. Only a small volume 1-2 µl of remaining PCR was 
then assessed by Dr. Michele Kiernan using an ABI Genetic analyser 3130, and 
the information analysed using Peak ScannerTM Software version 1.0 to 
produce electropherograms.  All fragments identified stutter peaks. Some of 
these results are presented in Figure 5. These results led us to choose 6534H 
as a fake maternal DNA. However the stutter peaks were clear from these 
results which could be due to CA repeat as it is dinucleotide repeat 
polymorphism. Other results of fragment analysis are shown in Appendix E.  
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Figure 5: Electropherograms (derived from Peak Scanner TM software) for selecting 
fake maternal DNA sample.  Y axis represents signal intensity peak height and X axis 
represents size base pairs. D21S1890 FAM labelled external forward and reverse 
primers were used at Td of 95 °C, the templates were different gDNA samples derived 
from buffy coat. A) Female gDNA is shown in red, and 0752D is shown in blue. Figures 
B, C and D are with the same female gDNA (red colour) compared with 6164Q, 615N 
and 6534H (all in blue) gDNA respectively. Sample 6534H was regarded as fake 
maternal DNA as it is clear from figure (D) that some peaks match female gDNA peaks 
and others are not matching. 
A 
B 
C 
D 
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3.4 Performing PCR with internal primers for fake fetal 
and maternal DNA 
 
End point PCR was performed for both fake fetal and fake maternal DNA, using 
D21S1890 FAM labelled internal forward and non-labelled internal reverse 
primers. AmpliTaq Gold enzyme was used as the first attempt for running these 
samples with internal primers at denaturation temperatures of 95 °C and 80 °C 
(expected product size of 101 bp). An aliquot of PCR amplicons was run on an 
agarose gel to check for the product size, the remaining PCR products were run 
on genetic analyser for fragment analysis. 
At a denaturation temperature of 95 °C with using AmpliTaq Gold enzyme, 
Figure 6 A shows an expected size product (101 bp) for both fake fetal and fake 
maternal DNA. However, fake maternal DNA shows faint band and a smaller 
band other than main band (Figure 6 A, lane 2) comparing to fake fetal DNA 
product at the same denaturation temperature, there is possible contamination 
as the negative control at both temperatures indicated contamination. While at a 
critical denaturation temperature of 80 °C, the result shows no amplification for 
the templates. The gel photo only shows primer dimer as seen in Figure 6 A 
lane 4 and lane 5. Results of running these samples on genetic analyser are 
presented in Appendix F. 
Moreover we have used AmpliTaq Gold enzyme with an extra step of heating 
mastermix, first at 95 °C for fifteen minutes in a separate PCR tube prior to 
adding templates. The result from this attempt was also unsatisfactory 
(Appendix G) as the gel photo showed no amplification of fake fetal and fake 
maternal DNA at a critical denaturation temperature of 80 °C. 
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Figure 6 : Agarose gel electrophoresis for PCR with D21S1890 FAM labelled internal 
forward and reverse primers using both AmpliTaq Gold and TaqMan mastermix.  
A) Using AmpliTaq Gold enzyme: lane M = DNA ladder, Lane 1 = fake fetal DNA at a 
Td of 95 °C, Lane 2 = fake maternal DNA (6534H) at a Td of 95 °C, Lane 3 = NTC. 
Lane 4, 5 and 6 same as lane 1, 2, and 3 but at a critical Td of 80 °C.   
B) Using TaqMan universal PCR mastermix: lane M = DNA ladder, lane 1 = fake fetal 
DNA at a Td of 95 °C, lane 2 = fake maternal DMA (6534H) at a Td of 95 °C and lane 3 
=NTC. Lane 4, 5 and 6 same as lane 1, 2, and 3 but at critical Td of 80 °C. 
 
 
 
 
A) 
B) 
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TaqMaster PCR Enhancer was also tried which is a buffer additive that 
improves thermostability (enzyme half-life) and processivity of Taq DNA 
polymerase by stabilizing the enzyme during PCR. It does not change the 
optimal primer annealing temperature or the melting behaviour of template 
DNA. PCR Enhancer was used with both AmpliTaq Gold enzyme and also with 
TaqMan mastermix. However, the agarose gel results indicated no difference 
between running these samples with or without PCR Enhancer as shown in 
Appendix H. Furthermore, the remaining portion of these PCR amplicons were 
run on genetic analyser for fragment analysis, to see if there is any possibility 
for stutter peaks elimination. However the electropherograms showed stutter 
peaks from running these samples with PCR Enhancer (Appendix I).  
Lastly TaqMan universal PCR mastermix was used as we knew that it definitely 
worked at both denaturation temperatures, as shown by the results of RT-PCR. 
Figure 6 B shows the results with using TaqMan indicating heteroduplex 
formation at both temperatures. At a denaturation temperature of 95 °C the 
result shows product with expected size of 101 bp for both fake fetal and fake 
maternal DNA (Lane 1 and Lane 2). While at critical denaturation temperature 
of 80 °C the result shows clear product for fake fetal DNA and unexpected 
product for fake maternal DNA with different product size (larger product size) 
(Figure 6 B, lane 4 and 5). NTC lanes show no contamination at both 
denaturation temperature (Figure 6 B, lane 3 and 6). 
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These final results (using TaqMan mastermix and with D21S1890 internal 
primers) were run on genetic analyser and compared with same samples but 
with D21S1890 external primers at a denaturation temperature of 95 °C. Figure 
7 indicates that the peak patterns look the same, but the shift in size of the 
product due to the different primers used for the PCR, and also there are 
enough differences between fake maternal and fake fetal DNA.  
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Figure 7 : Electropherogram (derived by Peak Scanner TM software) for both fake fetal 
and fake maternal DNA. Using internal and external D21S1890 primers, Y axis 
represents signal intensity peak height and X axis represents size base pairs. Maternal 
DNA (blue colour) and fetal DNA (red colour) 
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3.5 Spike experiment  
3.5.1 RT-PCR results 
The aim of the spiking experiment was to test if the fake fetal fragment would 
denature without denaturation of fake maternal DNA at critical denaturation 
temperature of 80 °C. After determining critical denaturation temperature by RT-
PCR, the spike experiment was performed, with fake fetal and fake maternal 
DNA being used as templates. As mentioned before (Method 2.5) four plates 
were prepared; two plates were run on StepOnePlus and the other two plates 
on the Veriti. On the StepOnePlus, one plate worked as positive control that all 
samples (small fake fetal fragment and large fake maternal DNA) would 
denature at 95 °C, while at 80 °C small fetal fragment would denature but not 
fake maternal DNA. For StepOnePlus we have used non-labelled internal 
D21S1890 forward and reverse primers and labelled D21S1890 probe. While 
for Veriti/end point PCR we used D21s1890 FAM labelled internal forward and 
non-labelled internal reverse primer. 
Figure 8 A and B shows standard curves (STD) at  denaturation temperatures 
of 95 °C and 80 °C, fake maternal DNA was used as STD at 95°C, while fake 
fetal DNA was used as STD at 80 °C. These results shows mean Ct value of 29 
for STD at a denaturation temperature of 95 °C, and mean Ct of 28 for STD at a 
critical denaturation temperature of 80 °C. 
At both denaturation temperatures NTC samples show no contamination as 
seen in Figure 8 C and D. The spike sample with composition of 90% of fake 
maternal DNA and 10% of fake fetal DNA shows amplification at both 
denaturation temperatures with mean Ct value of 6 at a denaturation 
temperature of 95°C and 26 at a critical denaturation temperature of 80°C 
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(Figure 8 C and D). Ct value of spike sample corresponds with fake fetal DNA at 
80°C which was 25 as shown in Figure 9 C. Fake maternal DNA showed 
amplification at a denaturation temperature of 95 °C with mean Ct value of 26 
(Figure 9 A), which is the same as Ct value for genomic DNA as presented in 
Figure 4 A, while Figure 9 B shows no amplification of fake maternal DNA at a 
critical denaturation temperature of 80 °C as expected. Results of spike sample 
with composition of 95% fake maternal DNA and 5% fake fetal DNA are shown 
in (Appendix K1 and K2). 
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Figure 8: RT-PCR amplification plots of spike experiment showing standard curve 
(STD) and spike sample at Td of 95 °C and 80 °C. A) Shows the STD of fake maternal 
DNA at a Td of 95 °C using different starting template dilutions, S1 (20ng/µl), S2 
(2ng/µl), S3 (0.2ng/µl) and S4 (0.02ng/µl). B) Shows standard curves of fake fetal DNA 
at critical Td of 80 °C using starting template dilutions S2 (2ng/µl), S3 (0.2ng/µl), S4 
(0.02ng/µl) and S5 (0.002ng/µl).  Figure C) and D) shows spike sample (90% fake 
maternal DNA: 10% fake fetal DNA) at Td of 95 °C and 80 °C respectively. NTC shows 
no contamination at both denaturation temperatures. 
 
 
 
 
A) B) 
C) D) 
75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9:  RT-PCR amplification plots of spike experiment showing both fake fetal and 
fake maternal DNA at Td of 95 °C and 80 °C, using TaqMan probe and D21S1890 
internal forward and reverse primers. A) At a Td of 95 °C the amplification plot shows 
amplification of both templates [fake fetal DNA (0.4 ng/µl) and fake maternal DNA (4 
ng/µl)]. B) At critical Td 80 °C fake fetal DNA shows amplification while fake maternal 
DNA is not amplified. C) Shows that both spike sample and fake fetal DNA are 
amplifying at critical Td of 80 °C with mean Ct of 26 and 25 respectively ( without 
amplification of fake maternal DNA (Ct value undetermined). 
 
 
 
A) B) 
C) 
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Samples (fake fetal DNA, fake maternal DNA and spike sample) were run out 
on agarose gels to check the size of the products. At a denaturation 
temperature of 95 °C Figure 10 A shows amplification of all templates, however 
the product from fake maternal DNA presents as a faint band (lane 7 and lane 
8) compared to the product of other templates at the same temperature. 
While at a critical denaturation temperature of 80 °C the result shows 
unexpected product for fake maternal DNA, furthermore the result shows a 
different product size (larger product size) as shown in lane 7 and lane 8 figure 
10 B. These results were consistent with the results from Figure 6 A. However 
running these same samples on an agarose gel showed product for fake 
maternal DNA at a critical denaturation temperature of 80 °C, which was 
unexpected, as RT-PCR results showed no amplification of fake maternal DNA 
at a critical denaturation temperature of 80 °C (Figure 9 B). The bands of fake 
fetal and spiked sample looked similar to each other on the gel which 
corresponds with RT-PCR results (both spiked sample and fetal DNA had mean 
Ct of 26 and 25 respectively). 
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Figure 10: Agarose gel of spiking experiment at Td of 95 °C and 80 °C. D21S1890 
FAM labelled internal forward and reverse primers were used.  
A)  Shows the results at a Td of 95°C:  
M =  DNA ladder, lane 1, 2, 3 and 4 are standard curve of fake maternal DNA (6534H) 
at a final concentration of 4 ng/µl, 0.4 ng/µl, 0.04 ng/µl and 0.004 ng/µl respectively. 
Lane 5= spike sample with composition of (90% maternal DNA + 10% fetal DNA) 
Lane 6 = spike sample with composition of (95% maternal DNA and 5% fetal DNA) 
Lane 7= fake maternal DNA (90%) 
Lane 8 = fake maternal DNA (95%) 
Lane 9 = fake fetal DNA (10%) 
Lane 10 = fake fetal DNA (5%)   
Lane 11 = NTC 
B) Shows the results of 80 °C critical Td, lane 1, 2, 3 and 4 are standard curves of fake 
fetal DNA at a final concentrations of 0.4 ng/µl, 0.04 ng/µl, 0.004 ng/µl and 0.0004 ng/µl 
respectively, the samples were loaded in lanes 5-11 in the same order as in figure 9 A. 
A) 
B) 
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The same products were run out on an acrylamide gel again to double check 
the product size difference. Figure 11 A shows the product from all samples 
(Spike sample, fake fetal and fake maternal DNA) at a denaturation temperature 
of 95 °C, however the fake maternal DNA bands looks extremely faint 
compared to that at 80 °C (Figure 11 B) which was completely unexpected. At a 
critical denaturation temperature of 80 °C, the product generated from both 
spiked sample and fake fetal DNA are smaller than expected size, they were 
both different from fake maternal DNA which presented in clear band and higher 
product size (Figure 11 B lane 3 and lane 4).  
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Figure 11: Non denaturing polyacrylamide gel electrophoresis result of spiking 
experiment at Td of 95 °C and 80 °C Td, Stained with Gel Red. A)  Shows the results 
at a Td of 95 °C run: M =DNA ladder, lane 1 = spike sample with composition of 90% 
maternal DNA + 10% fetal DNA, lane 2 = spike sample with composition of 95% 
maternal DNA and 5% fetal DNA, lane 3= fake maternal DNA (90%), lane 4 = fake 
maternal DNA (95%), lane 5 = fake fetal DNA (10%), lane 6 = fake fetal DNA (5%). B) 
Shows the results at a critical Td of 80 °C, the order of loading for the samples were 
The same as in figure 10 A. 
A) 
B) 
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3.5.2 Fragment analysis result 
Figure 12 shows the fragment analysis result for the spike experiment at 
denaturation temperatures of 95 °C and 80 °C. At a denaturation temperature of 
95 °C the peaks were coming from all samples (fake fetal DNA, fake maternal 
DNA and spike sample), which confirms the result from RT-PCR (which showed 
amplification from all templates at a denaturation temperature of 95 °C). At 
critical denaturation temperature 80 °C fragment analysis result showed 
absence of fake maternal DNA peaks. It is not complete absence but 
nevertheless it is not the same as peaks of fake maternal DNA at a denaturation 
temperature of 95 °C. 
The spike sample (90% maternal DNA and 10% fetal DNA) matches fake fetal 
DNA in both electropherograms. We would expect this match at critical 
denaturation temperature 80 °C but at 95 °C the spike sample was expected to 
also correspond to the maternal peaks but it does not as shown in figure 12 A 
and B. Also these results indicate that the product of spike sample is 
predominantly from fake fetal DNA sample and not from fake maternal DNA. 
Again this was supported by the same result of RT-PCR result which showed 
close Ct value between fake fetal and spike sample at a critical denaturation 
temperature of 80°C (mean Ct value of 25 and 26 respectively) with no 
amplification of fake maternal DNA (Ct value undetermined). 
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Figure 12: Electropherogram derived by (Peak Scanner TM software) for the spike 
experiment at Td of 95 °C and 80 °C. Y axis represents signal intensity peak height 
and X axis represents size in base pairs. D21S1890 FAM labelled internal forward and 
reverse primers were used. A) Shows result at a Td of 95 °C, spike sample (green), 
fake maternal DNA sample (blue) and fake fetal DNA (red). B) Shows the results at 
critical Td 80 °C, spike sample (green), fake maternal DNA sample (blue) and fake fetal 
DNA (red). The area of graph B where there is absence of maternal peaks is labelled 
clearly showing that maternal fragments have failed to be amplified in this region by 
COLD-PCR. Blue arrows point out few maternal peaks at Td of 80°C 
  
 
 
 
A) 
B) 
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3.5.3 SYBR Green assay  
3.5.3.1 RT-PCR result 
RT-PCR using SYBR Green mastermix was performed, using D21S1890 
internal forward and reverse primers and the templates were spike sample 
(90% fake maternal DNA + 10% fake fetal DNA), fake maternal DNA alone 
(90 %) and fake fetal DNA alone (10 %); again at two different denaturation 
temperatures (95°C and 80°C).  
The RT-PCR results indicate that at a critical denaturation temperature of 95 °C 
fake maternal DNA, fake fetal DNA and spike sample are all amplified. The 
mean Ct value for the fake maternal DNA, fake fetal DNA and spike samples 
were 3, 24 and 4 respectively as shown in Figures 13 A and C. At critical 
denaturation temperature of 80 °C fake maternal DNA showed amplification 
with Ct value of 32 (Figures 13 B and E). This result was unexpected as the 
results of RT-PCR with TaqMan probe showed no amplification of fake maternal 
DNA (Figure 9 B), and also the results of RT-PCR for identifying critical 
denaturation temperature showed no amplification of genomic DNA sample at 
80°C as presented in Figure 4 B. Both fake fetal DNA and spike sample showed 
amplification at 80 °C critical denaturation temperature with mean Ct value of 27 
for fake fetal DNA and 15 for spike sample. The negative water control at 
denaturation temperature of 95 °C and 80 °C indicated contamination as shown 
in Figures 13 C and D). 
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Figure 13: RT-PCR amplification plot for the spike experiment using SYBR Green at 
Td of 95 °C and 80 °C. A) RT-PCR amplification plot at Td of 95 °C showing 
amplification of both fake fetal and fake maternal DNA with mean Ct value of 3 and 24 
respectively. B) RT-PCR amplification plot at critical Td of 80 °C, showing amplification 
of fake fetal DNA with mean Ct value of 27 and fake maternal DNA showed 
amplification with late mean Ct value of 32. C) RT-PCR amplification plot at 95 °C 
showing spike sample (90% fake maternal DNA + 10% fake fetal DNA) with mean Ct 
value of 4 and negative water control. D) RT-PCR amplification plot at 80 °C showing 
spike sample (90% fake maternal DNA + 10% fake fetal DNA) with mean Ct value of 
15 and negative water control. E) RT-PCR amplification plot at 80 °C showing spike 
sample, fake maternal and fetal DNA. 
A) B) 
C) D) 
E) 
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3.5.3.2 Melt curve analysis 
The use of SYBR Green allows melt curve analysis to be performed. Following 
RT-PCR, the amplicon amplified should have been exactly the same for both 
fake maternal DNA and fake fetal DNA and therefore each denaturation 
temperature should have indicated the same melting temperature (Tm) with 
melt curve analysis. However the results showed that the Tm of the amplicon 
produced at critical denaturation temperature of 80°C was lower than Tm of 
amplicon produced from same template at 95°C (Figure 14 A, B and C); this 
difference was 4.15°C in fake maternal and 3.24°C for the fake fetal DNA, 
whereas spike sample showed same Tm at both runs. The fake maternal DNA, 
fetal DNA and spike samples have obvious shoulder peaks at critical 
denaturation temperature of 80 °C, indicating the amplification of products with 
differing sequences possibly as a result of heteroduplex formation or 
contamination (Figures 14 D, E and F). We expected to see the same Tm for 
both spike sample and fake fetal DNA at the critical denaturation temperature of 
80 °C; however the result showed different Tm values, indicating that the spike 
sample may not solely derive from fake fetal DNA. These results were 
consistent with RT-PCR results as presented in Figures 13 B and C, in which 
the replicates of the samples (fake maternal DNA, fake fetal DNA and spike 
sample) were not in agreement.    
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Figure 14: Melt curves of RT-PCR products of spike experiment at Td of 95 °C and 80 
°C, showing fake fetal DNA, fake maternal DNA and spike sampleS. From left to right 
graphs show the melt curves of fake maternal, fetal and spike templates products. The 
top row show the curves from the products at Td of 95 °C (A, B and C) and the bottom 
row show the curves of products at critical Td 80 °C critical denaturation 
temperature(D, E and F). 
 
 
  
 
 
 
 
 
 
A) B C) 
D) E) F) 
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3.6 Cloning experiment 
The purpose of the cloning experiment was to clone the PCR product at 
denaturation temperatures of 95 °C and 80 °C for both fake fetal DNA 
(produced from female genomic DNA) and fake maternal DNA (6534H from 
buffy coat) and then sequence them to see the representation of CA repeat. 
TOPO TA Cloning® Kit for Sequencing was used for this purpose. 
Fake fetal and fake maternal DNA were used as templates to perform a PCR 
with D21S1890 internal forward and reverse primers, at denaturation 
temperatures of 95 °C and 80 °C. This was performed to generate insert 
(expected size 101 bp) to be used for the cloning experiment. At the same time 
another PCR was performed with D21S1890 external forward and reverse 
primers, for fake fetal DNA and female genomic DNA at a denaturation 
temperature of 95 °C, this was to generate insert (expected size 229 bp) for the 
cloning experiment. Figure 15 shows agarose gel electrophoresis result for 
these PCR products (with denaturation temperatures 90°C and 80°C). These 
results indicate a clear product amplification of around 229 bp (lane 1= fake 
fetal DNA and lane 2= fake maternal DNA), both at a denaturation temperature 
of 95 °C. However running same templates with D21S1890 internal forward and 
reverse primers showed smaller products as well as the expected amplified 
fragment (101 bp) (Figure 15 lane 3 and 4 at 95 °C; lane 5 and 6 at 80 °C), 
therefore gel purification was done. Instead of having two samples at each 
temperature the total numbers of samples was four samples at each 
temperature. Once DNA had been purified it was quantified using the Nano Vue 
Plus (GE Healthcare) spectrophotometer. The concentrations were calculated 
from absorbance reading and are presented in Table 6. 
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Figure 15: Agarose gel of PCR for the cloning experiment at Td of 95 °C and 80 °C 
M=DNA ladder, lane 1= fake fetal DNA, lane 2= fake maternal DNA, both at Td of 95 
°C using D21S1890 external forward and reverse primers. Approximately 229 bp PCR 
amplicon was generated and used as insert for the cloning experiment. Lane 3= fake 
fetal DNA, lane 4= fake maternal DNA both at a Td of 95 °C but with D21S1890 
internal forward and reverse primers. Approximately 101 bp PCR amplicon was 
generated and used as insert for the cloning experiment. Lane 5= fake fetal DNA, lane 
6= fake maternal DNA both at critical Td of 80 °C with D21S1890 internal forward and 
reverse primers. Positive water contamination clearly seen in NTC lanes 
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Table 6: Assessment of DNA quality and quantity for PCR purification of fake 
fetal and fake maternal DNA at Td of 95°C and 80°C. 
 
 
 
 
 
 
 
 
  
Samples  Concentration A260/A280 
ratio 
A260/A230  
ratio 
Fake fetal DNA 
at Td of 95 °C 
Band 1 6.6 ng/µl 3.220 0.019 
Band 2 2.4 ng/µl 0.757 0.007 
Fake maternal 
DNA at a Td of 
95 °C 
Band 1 2.0 ng/µl 0.609 0.005 
Band 2 5 ng/µl 0.833 0.011 
Fake fetal DNA 
at critical Td of  
80 °C 
 
Band 1 11.7 ng/µl 4.588 0.010 
Band 2 5.7 ng/µl 1.754 0.009 
Fake maternal 
DNA at a critical 
Td of  80 °C 
Band 1 4.4 ng/µl 2.289 0.027 
Band 2 6.0 ng/µl 0.656 0.027 
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First attempt was to clone the PCR product of fake maternal DNA and female 
genomic DNA (with external primers, at a denaturation temperature of 95°C).  
The Rapid One Shot® Chemical Transformation protocol was followed 
according to manufacturer’s instructions. This is an alternative protocol 
recommended to obtain transformant as quickly as possible and it is also 
recommended for transformations using ampicillin selection. Thus after 
performing the TOPO® Cloning Reaction (Method 2.7.4), the Cloning Reaction 
was directly added into two vial of One Shot Chemically Competent E.coli, and 
after five minutes of incubation the mixture were spread on a prewarmed LB 
plate containing ampicillin and X-gal and incubated overnight at 37°C. The 
plates showed no colonies for both templates the following day.  
When this attempt failed, the same PCR products were used but this time trying 
the One Shot Chemical Transformation Protocol, which includes heat shocking 
the cells for thirty seconds at 42°C and adding S.O.C medium. So samples from 
the first attempt were used (fakel feta DNA and female genomic DNA with 
external primers at a denaturation temperature of 95 °C) in addition to fake fetal 
DNA sample with internal primer, at a critical denaturation temperature of 80 °C. 
After 24 hour overnight incubation, the plates produced blue/white colonies. 
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Even though blue/white screening can be used to determine if inserts are 
present, colony PCR was performed to screen for plasmid inserts. Nine colonies 
were picked at random for colony PCR for each template (fake fetal DNA, 
female genomic DNA at a denaturation temperature of 95 °C with external 
primers and fake fetal DNA at critical denaturation temperature of 80 °C with 
D21S1890 internal primers). Agarose gel result showed no product for all of 
templates (data not shown), indicating the likelihood that the plasmids were 
without inserts.  
Next attempt was repeating the cloning experiment but with the following 
changes to the protocol:  
 Performing PCR with BioMixTM DNA polymerase instead of TaqMan 
polymerase enzyme. 
 Final extension step of PCR condition was changed to ten minutes 
instead of twenty minutes (Method 2.4.6). 
 Instead of performing gel purification for the PCR product, cleaning of the 
PCR product was done using QG buffer and isopropanol (Method 2.8.1). 
 For the TOPO® Cloning Reaction 1 µl of fresh PCR product was used 
instead of 4 µl. 
For performing a PCR, female genomic DNA and fake maternal DNA were used 
as templates and the PCR was performed with a denaturation temperature of 
95 °C. Figure 16 shows the result of agarose gel electrophoresis of this PCR, as 
it shown there is single band for each template around 229 bp; however the 
marker was not clear. Water contamination observed in lane 3. 
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Figure 16: Agarose gel of PCR for female gDNA and fake maternal DNA at a Td of 95 
°C. D21S1890 external forward and reverse primers were used to generate PCR 
amplicons to be used as inserts for the cloning experiment. M= DNA ladder, lane 1= 
female gDNA, lane 2= fake maternal DNA and lane 3= NTC 
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Once DNA had been cleaned it was quantified using the NanoVue Plus 
spectrophotometer (GE Healthcare). Concentrations were calculated from 
absorbance readings and are presented in Table7. 
 
 
Table 7: Assessment of DNA quality and quantity for PCR cleaning of female 
gDNA and fake maternal DNA at Td of 95 °C. 
sample Concentration A260/A280 ratio A260/A230 ratio 
Female genomic 
DNA at a Td 95 °C 
20.5ng/µl 1.708 0.061 
Fake maternal 
DNA at a Td 95 °C 
20.0ng/l 1.674 0.325 
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After spreading the transformation on a prewarmed plate (containing ampicillin 
and X-gal), plates were incubated overnight at 37 °C. The next day the plates 
showed blue/white colonies for only one template (Female genomic DNA) and 
no colonies for the other template (fake maternal DNA). Five white colonies 
were picked from the plates for female genomic template, plus one blue colony 
for colony PCR. This was done to double check if we were getting the right 
insertion from this PCR product because no colonies were seen with the other 
PCR product, before carrying out sequencing.  
Figure 17 shows product with expected size of ~330 bp for white colonies (229 
bp PCR product size + 100 bp vector sequence including M13 primer 
sequences). This result Indicated the plasmids contained the right inserts, 
however the gel photo shows unexpected product from blue colony which is 
larger than 100 bp. Theoretically the blue colony is without insert; hence we 
expected to see a product with 100 bp size (just vector sequence without 229 
bp PCR product). 
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Figure 17: Agarose gel of colony PCR to assess presence of inserts in vector. Female 
gDNA was used as a template for the insert PCR. M13 forward and reverse primers 
were used for colony PCR, lane 1, 2, 3, 4 and 5= white colonies of female gDNA, lane 
6=blue colony  
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The next step was isolation of plasmid containing the insert from bacterial cells. 
Single colonies were picked from the plates and were grown overnight in LB 
medium containing ampicillin. Plasmid DNA was purified using Miniprep Kit after 
16 hours incubation (Method 2.7.7). The concentration of five samples was 
measured using Nano Vue Plus spectrophotometer (GE Healthcare). 
Concentrations were calculated from absorbance reading and are presented in 
Table 8. Finally, all five miniprep samples were sent for sequencing.  
 
Table 8: Assessment of DNA quality and quantity for the five miniprep samples 
of female gDNA. 
Samples Concentration A260/A280 ratio  A260/A230 ratio  
Sample 1 77.5 ng/µl 2.067 2.460 
Sample 2 85.05 ng/µl 2.099 2.881 
Sample 3 109.05 ng/µl 2.019 2.449 
Sample 4 84.05 ng/µl 2.112 2.561 
Sample 5 90.5 ng/µl 2.080 2.919 
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The sequencing results for the starting template of female genomic DNA were 
aligned with the reference chromosome (chromosome 21, Appendix A). the 
result showed the different number of CA repeats for each of miniprep, as 
presented in Figure 18.  
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*        20         *        40         *        60         *        80         *       100         *       120 
D21S1890 : GGAGAAACGAGGATGAGCTTCTCCTCATTCGCCCGAGGGTCTGACCACAGATTTCCCAATCGCCACACACACACACACACACACACACACACACACACACACAC--------------GGGTTG : 110 
1F       : GGAGAAACGAGGATGAGCTTCTCCTCATTCGCCCGAGGGTCTGACCACAGATTTCCCAATCGCCACACACACACACACACACACACACACACACACACACACAC--------------GGGTTG : 110 
5F       : GGAGAAACGAGGATGAGCTTCTCCTCATTCGCCCGAGGGTCTGACCACAGATTTCCCAATCGCCACACACACACACACACACACACACACACACACACACACAC--------------GGGTTG : 110 
4F       : GGAGAAACGAGGATGAGCTTCTCCTCATTCGCCCGAGGGTCTGACCACAGATTTCCCAATCGACACACACACACACACACACACACACACACACACACACACACACA----CACACACGGGTTG : 120 
2F       : GGAGAAACGAGGATGAGCTTCTCCTCATTCGCCCGAGGGTCTGACCACAGATTTCCCAATCGACACACACACACACACACACACACACACACACACACACACACACATACACACACACGGGTTG : 124 
3F       : GGAGAAACGAGGATGAGCTTCTCCTCATTCGCCCGAGGGTCTGACCACAGATTTCCCAATCGACACACACACACACACACACACACACACACACACACACACACACA------CACACGGGTTG : 118 
     GGAGAAACGAGGATGAGCTTCTCCTCATTCGCCCGAGGGTCTGACCACAGATTTCCCAATCG CACACACACACACACACACACACACACACACACACACACAC              GGGTTG 
 
*       140         *       160         *       180         *       200         *       220         *       240 
D21S1890 : TTTGGGAGTCAGTTGGTTTTCAAAGGCTTTCAAGGAAATGAAGAGTCCCAAAGTTTTCCTTAATCGTTCAGAGTGTTTTTCTTTGTCCCAGGTTTATATACCAAGAATACGGGGGAATA : 229 
1F       : TTTGGGAGTCAGTTGGTTTTCAAAGGCTTTCAAGGAAATGAAGAGTCCCAAAGTTTTCCTTAATCGTTCAGAGTGTTTTTCTTTGTCCCAGGTTTATATACCAAGAATACGGGGGAATA : 229 
5F       : TTTGGGAGTCAGTTGGTTTTCAAAGGCTTTCAAGGAAATGAAGAGTCCCAAAGTTTTCCTTAATCGTTCAGAGTGTTTTTCTTTGTCCCAGGTTTATATACCAAGAATACGGGGGAATA : 229 
4F       : TTTGGGAGTCAGTTGGTTTTCAAAGGCTTTCAAGGAAATGAAGAGTCCCAAAGTTTTCCTTAATCGTTCAGAGTGTTTTTCTTTGTCCCAGGTTTATATACCAAGAATACGGGGGAATA : 239 
2F       : TTTGGGAGTCAGTTGGTTTTCAAAGGCTTTCAAGGAAATGAAGAGTCCCAAAGTTTTCCTTAATCGTCCAGAGTGTTTTTCTTTGTCCCAGGTTTATATACCAAGAATACGGGGGAATA : 243 
3F       : TTTGGGTGTCAGTTGGTTTTCAAAGGCTTTCAAGGAAACGAAGAGTCCCAAAGTTTTCCTTAATCGTTCAGAGTGTTTTTCTTTGTCCCAGGTTTATATACCAAGAATACGGGGGAATA : 237 
     TTTGGGaGTCAGTTGGTTTTCAAAGGCTTTCAAGGAAAtGAAGAGTCCCAAAGTTTTCCTTAATCGTtCAGAGTGTTTTTCTTTGTCCCAGGTTTATATACCAAGAATACGGGGGAATA 
 
 
Figure 18: Multiple alignment of DNA sequence (chromosome 21, D21S1890) for female genomic DNA sample at a denaturation temperature of 
95°C. M13 forward primers used for sequencing five random white colonies, the result of sequencing from different colonies were compared with 
D21S1890 product with external primers. The yellow sections indicate D21S1890 external forward and reverse primers; the green section indicates 
different number of CA repeats between each sample. Base pair T (highlighted in red) most probably due to sequencing error. 
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To test for plasmid DNA with the correct insert and also to see how the CA 
repeats looked on an acrylamide gel, purified DNA was digested with EcoRI 
(Method 2.8.8). The resulting DNA fragments were separated on acrylamide 
gel. The acrylamide gel electrophoresis results showed bands within the 
expected size (229 bp) (Figure 19), also the results showed that two of the 
samples (Lane 3 and 5) showed same product size, sequencing results of these 
two samples showed same number of CA repeat (20) as shown in Figure 19 1F 
and 5F. 
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Figure 19: Non denaturing polyacrylamide gel for the restriction enzyme to confirm the 
insert of female gDNA in pCRTM4-TOPO® TA vector.  10% acrylamide gel stained with 
Gel Red was used for five white colony samples of female gDNA. M= DNA ladder, 
lane1, 2, 3, 4 and 5 different white colonies of female gDNA template. 
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The next step was to repeat the running of a PCR for the fake maternal DNA 
template. Therefore PCR was performed with D21S1890 external forward and 
reverse primers using BioMix DNA polymerase at a denaturation temperature of 
95°C (Method 2.3.6). A portion of the PCR product was initially run across an 
agarose gel. This was to verify that product had been amplified and that it was 
of the correct size. The gel photo showed that the template had given a faint 
band at approximately 229 bp as expected as shown in Appendix L. Then 
cleaning of the product was done (Method 2.7.1). Once the DNA had been 
cleaned, it was quantified using the NanoVue Plus spectrophotometer (GE 
Healthcare). Concentrations were calculated from absorbance readings: the 
concentration was 12.1ng/µl and the A260/A280 ratio was 1.806, and the 
A260/A230 ratio was 0.025. TOPO® Cloning Reaction and transforming to E.coli 
cells was done same as before. The plates did not show any colonies for the 
first twenty four hours, but after forty eight hours the plates showed blue/white 
colonies. However, the white colonies were smaller and fewer in number than 
the blue colonies. Colony PCR was done for ten of the white colonies. Figure 20 
indicates that the plasmids were without the inserts.  
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Figure 20: Agarose gel of colony PCR for fake maternal DNA (6534H). D21S1890 
external forward and reverse primers were used to generate PCR amplicons to be 
used as inserts for the cloning experiment. M13 forward and reverse primers were 
used for colony PCR, M= DNA ladder, lanes 1-10 are different white colonies of fake 
maternal DNA. 
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With limited time to complete the project, it was not possible to order a new 
cloning kit for repeating the cloning experiement. A PhD student Kelly Sillence 
(Plymouth University) was able to repeat the cloning experiment using a new 
cloning kit but with same fake fetal DNA sample. Therefore the cloning 
experiment was repeated for fake fetal DNA template at denaturation 
temperatures of 95 °C and 80 °C. The sequencing results showed no 
sequencing for the CA repeat region at the critical denaturation temperature of 
80 °C for fake fetal DNA sample (the result is presented in Appendix M). 
However this result shows drop out of more than just the CA repeat region at a 
critical denaturation temperature of 80 °C. The sequencing was done for two 
white colonies chosen at random, so sequencing of more colonies at critical 
denaturation temperature of 80 °C would maybe more informative. 
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4 Chapter Four 
4.1 Discussion  
Testing for birth defects and inherited diseases during pregnancy first became 
possible in the late 1960’s with the development of lab techniques that were 
able to grow fetal cells found in amniotic fluid. The foremost reason that 
pregnant women decide to enter any kind of prenatal screening programme is 
for the detection of aneuploidy, in particularly Down syndrome, which is the 
most common cytogenetic anomaly in live births. Other fetal aneuploidies 
frequently detected involve chromosomes 13 (Patau syndrome) or 18 (Edwards 
syndrome). Once the chromosomal abnormality responsible for the phenotypic 
appearance of Down syndrome had been identified, it became possible to make 
a firm diagnosis based on cytogenetic studies (Maliszewski, 2010),  
Currently, prenatal diagnosis of aneuploidies relies on invasive procedures such 
as CVS in the first trimester and amniocentesis in the second trimester. 
Following these procedures, the full fetal karyotype is usually determined using 
cultured cells. The two weeks period needed for cultivation and subsequent 
analysis has proven to be associated with considerable parental anxiety and 
medical problems in those situations requiring therapeutic intervention. The 
disadvantages of CVS and amniocentesis are that they involve introducing a 
needle into the uterus, which is associated with the risk of morbidity and 
mortality and transmission of infection to the fetus at the time of the invasive 
procedure (Giorlandino et al., 1994). 
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It is because of these procedure-related risks, and how they are assessed 
against the value of the information obtained, that many women opt to refuse 
having prenatal diagnostic testing. For some women, despite wanting the 
information or considering it valuable, they are simply not willing to risk 
miscarriage. If a woman chooses not to have diagnostic testing, the most 
knowledge she can gain is through combining ultrasound findings with maternal 
serum screening. Miscarriage is not associated with either of these screening 
methods; however they are not diagnostic tests. 
As the invasive procedures bear a considerable risk for fetal loss, a long sought 
goal in prenatal medicine is the establishment of non-invasive tests that allow 
for prenatal genetic testing. The traditional strategy to accomplish this goal was 
focused on fetal nucleated cells found in the maternal circulation (Herzenberg et 
al., 1979, Lo et al., 1997). However a number of obstacles including their 
persistence in maternal circulation after pregnancy, rarity and lack of fetal 
specific markers, meant that another approach needed to be found (Bianchi et 
al., 1996, Avent et al., 2008). The later discovery of cffDNA in maternal plasma 
(Lo et al., 1997) has shifted the attention towards this target. cffDNA disappears 
rapidly from the maternal circulation postpartum (Lo et al., 1999), this means 
that it is pregnancy specific and would not lead to false positive results in future 
pregnancies. 
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The developing possibilities of NIPD may lead to significant changes in the 
testing and screening of pregnancies. Research on non-invasive testing began 
by examining the placental barrier between mother and fetus. The result 
obtained indicated that the fetus could release its DNA and RNA into the 
mother’s circulation. So initially, interest was focused on genes, gene products 
and/or mutations that are passed on to the fetus by the father and which were 
distinguishable from those of the mother. Although some work has been carried 
out using fetal cells obtained from the cervical mucus (Mantzaris et al., 2005) or 
fetal DNA in maternal urine (Shekhtman et al., 2009).  
Most research has been focused on strategies to detect cffDNA from the fetus 
in the maternal circulation. A number of clinical applications of cffDNA analysis 
for prenatal screening and/or diagnosis have been developed, based on distinct 
and detectable differences between fetal and maternal genome like fetal sex or 
fetal Rhesus D status. Fetal sex determination is feasible and reliable using 
cffDNA from 7 weeks of gestation through the detection of sequences on the Y 
chromosome and has been available to all women at risk of X-linked disorders 
(Costa et al., 2002, Finning et al., 2002, Avent and Chitty, 2006), and congenital 
adrenal hyperplasia (Rijnders et al., 2004). It has been estimated that this 
application may reduce the need for invasive testing by 50% (Finning and 
Chitty, 2008). A study by Hill et al. (2011) investigating the NHS costs of NIPD 
and invasive prenatal diagnosis, showed that the costs of NIPD and invasive 
prenatal tests are similar for fetal sex determination. Hence, NIPD can provide 
benefits for many women by avoiding the risks of invasive testing, without 
acquiring additional costs.  
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In addition fetal RhD status determination has widely been used in pregnancies 
involving RhD-negative women (Lo et al., 1998, Finning et al., 2004, Scheffer et 
al., 2011). Sbarsi et al. (2011) demonstrated accurate procedures for 
determining of fetal RHD genotype, thus permitting early diagnosis of at risk 
pregnancies and the correct management of HDFN. This enables unnecessary 
treatments to be avoided, and prevents wastage of anti-D immunoglobulins. 
NIPD is limited by the minimal quantity of fetal sample available for analysis and 
thus requires the application of new technologies with extremely high sensitivity. 
The problem with detecting cffDNA is that it appears in low concentration 
against a background of maternal DNA (Chan et al., 2004, Li et al., 2004b). 
RT-PCR had been employed as a conventional tool to amplify cffDNA, aiming to 
enrich cffDNA and ultimately to be able to detect aneuploidies. The downside of 
this method is that it does not just amplify cffDNA but also maternal DNA. This 
raises the need for distinguishing features between the DNA of mother and 
baby. Therefore, COLD-PCR was tried as an alternative method to enrich for 
cffDNA against a maternal background. 
In this study we have attempted to test the theory that COLD-PCR could be 
used to selectively amplify fetal DNA. The denaturation temperature of cffDNA 
is predicted to be lower due to its smaller fragment size, and this might mean it 
could be selectively amplified with COLD-PCR. This investigation focused on a 
fragment on chromosome 21 containing a CA repeat STR, identified as 
D21S1890. 
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Fake fetal DNA was generated from female genomic DNA (Promega) using 
D21S1890 external forward and reverse primers. 6534H genomic DNA (from 
buffy coat) was regarded as fake maternal DNA. This was selected from twenty 
four genomic DNA samples after comparing it with female genomic DNA 
sample, in which the results from fragment analysis showed matching and 
distinguishing peaks between them, as shown in Figure 5 D. 
The first step was trying to find the critical denaturation temperature, at which 
fake fetal DNA would denature while fake maternal DNA would remain double 
stranded and not amplified. Hence enrichment of the fetal DNA fragment can 
then be used for simple methods of detecting trisomy such digital PCR. The 
only limitation with methods such as digital PCR is the low concentration of fetal 
DNA in the maternal circulation, thus prior enrichment of the fetal DNA is 
required for these methods. 
Early experiments tried to repeat the same critical denaturation temperature that 
had been identified before (unpublished work in Neil Avent’s lab). The previous 
work was done using end point, conventional PCR and then running samples 
on an agarose gel to check for the product size. The previous results 
determined that 78.8 °C was the critical denaturation temperature. However the 
results from running RT-PCR with the identified critical denaturation 
temperature (78.8 °C), using fake fetal DNA were negative i.e. no amplification 
of the DNA templates (fake fetal DNA and female genomic DNA) (Appendix 
C1), which meant that this temperature was too low even to amplify fake fetal 
DNA. 
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Therefore, the next step was to test different denaturation temperatures in an 
attempt to find the critical temperature for the selective amplification of fetal 
DNA. A denaturation temperature of 79.4 °C was also tried but again the result 
showed no amplification of fake fetal DNA. A range of denaturation 
temperatures between 84 °C and 81°C were tested. At 84 °C the results 
showed amplification of both fetal and genomic DNA with mean Ct value of 30 
for fetal DNA however the genomic DNA was undetermined but the fetal DNA 
showed amplification at very late cycles as shown in Figure 4 B. At denaturation 
temperature of 83 °C the mean Ct value for fake fetal DNA was 32, so by 
getting the denaturation temperature lowered to 82°C we were getting 
amplification of just fake fetal DNA but at the late cycles. 
So another range of temperatures were tested to find the temperature at which 
fake fetal DNA would amplify at an earlier cycle  but with no amplification of 
genomic DNA at the same temperature. Temperatures of 81.8 °C- 81.6 °C- 
81.4 °C- 81.2 °C and 80 °C were tested for this reason. At 81.6 °C and 81.4°C 
the results showed amplification of both fake fetal DNA and genomic DNA 
however the genomic DNA template were amplifying at very late cycles. RT-
PCR at a denaturation temperature of 81.2 °C showed mean Ct value for fake 
fetal DNA of 22 and undetermined Ct value for female genomic DNA. However 
this PCR run showed contamination in all NTC replicates, despite of repetition 
of the PCR run, therefore this temperature was not identified as the critical 
denaturation temperature (Appendix C2).  
  
109 
 
Thus identifying 80 °C as critical denaturation temperature for this study was 
based on the following: getting amplification of fake fetal DNA at early cycles 
without amplification of genomic DNA, mean Ct value for fake fetal DNA was 29 
(Figure 4 C).  
Since the fake fetal DNA was generated from female genomic DNA, fake 
maternal DNA was needed for establishing the spike experiment which required 
making a sample of mixed composition of fake maternal and fetal DNA that 
imitated the blood sample of a pregnant woman, which is a mixture of fetal and 
maternal DNA. As mentioned before different genomic DNA samples from buffy 
coat were tested in an attempt to find fake maternal DNA. Fragment analysis 
was done for all these genomic DNA samples, and female genomic DNA was 
compared with each of these samples depending on the fact that every person 
will have two alleles: one from mother and the other from father so ideally we 
should have two peaks for the fake fetal DNA and for identifying fake maternal 
DNA we should find a sample with one peak matching fetal peaks and another 
not matching fetal peaks see (Figure 21).  
  
110 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Schematic diagram showing the fragment length of alleles from a 
heterozygous fetus along with the alleles of the mother and father (both also 
heterozygous). This explains why, when looking for a fake fetal and maternal pair, the 
pair should ideally have a matching and distinguishing allele. This diagram also shows 
the fragment lengths as they should appear: without stutter bands. 
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The peaks representing allele size are separated by multiples of two base pairs, 
as expected for a CA STR sequence. However, as each individual has only two 
alleles the observed result of multiple peaks was not expected. Despite the 
stutter peaks in the fragment analysis result, the genomic DNA sample (6534H) 
was identified for use as fake maternal DNA. A stutter peak was one of the main 
issues that were highlighted in this study. 
Stutter peaks 
Stutter products are regarded as a biological artefact of STR marker analysis, 
which makes mixture analysis more difficult. Stutter pattern is less pronounced 
with larger repeat unit sizes, which means that it occurs more with dinucleotide 
repeats than with tri- or tetra-nucleotide repeats (Murray et al., 1993). A 
mechanism known as slipped strand mispairing has been proposed to explain 
the stutter bands that result from the amplification of dinucleotide repeats. 
According to this proposal, the template strand and extending strand can 
spread apart during synthesis through the repeat region perhaps when the DNA 
polymerase has fallen off during the PCR. A single unit can then loop out in the 
template strand before the two strands are reannealed. The result is that the 
newly extended strand will have one fewer repeat unit than the template strand 
when synthesis is complete (Walsh et al., 1996).  
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Miller & Yuan,(1997) demonstrated that a major problem of doing quantitative 
analysis of genomic STR is the stutter pattern. They proposed that stutter 
patterns may arise from factors such as Taq Polymerase misreading or 
secondary structure of DNA.  
Kellogg et al. (1994) explained that stutter patterns can be reduced, and 
sometimes eliminated, by optimizing PCR conditions using different primers and 
using hot-start PCR. They showed that the change in size distribution with 
increasing cycle count implies that the stutter is due to Taq Polymerase 
skipping or gaining a dinucleotide repeat, rather than arising from DNA 
secondary structure and the explanation is because if the stutter were due to 
secondary structure, the pattern would be expected to remain constant during 
amplification.  
Moretti et al.(1998) demonstrated that the AmpliTaq Gold DNA polymerase is a 
thermostable enzyme which effectively simulates (hot start) PCR in a fast, 
simple and practical fashion. The use of this enzyme can reduce or eliminate 
the generation of non-specific PCR products that can result from mispriming 
and primer oligomerization with the use of some primers and substandard 
reaction conditions. This group clarified that the undesired PCR products 
compete with targeted sequences for dNTPs and primers and, as a result, 
reduce the yield of specific target products. They assessed the usefulness of 
AmpliTaq Gold DNA polymerase in a multiplex STR amplification system that 
exhibited a non-specific PCR product and poor yield at two of the four loci when 
AmpliTaq DNA polymerase was used (Forslund et al., 1999, Thompson et al., 
1998). 
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In the spike experiment, we have imitated the environment for cffDNA during 
early and late pregnancy by having different mixtures of fake fetal and fake 
maternal DNA. For the early pregnancy the simulation we used was 5% of fake 
fetal DNA, while for the late pregnancy we used 10%. A study by (Lo et al., 
1998) showed the concentration of cffDNA to be 3.4% and 6.2% of the total 
plasma DNA in early and late pregnancy respectively. So we were broadly 
trying to establish differences between first and third trimesters.  
RT-PCR results of spike experiment clearly showed amplification of fake fetal 
DNA without amplification of fake maternal DNA at the critical denaturation 
temperature (80°C). However running the same templates under the same 
conditions but with D21S1890 FAM labelled internal forward and reverse 
primers (without using D21S1890 probe) on conventional/end point PCR, the 
agarose gel showed a product at 80 °C critical denaturation temperature for the 
fake maternal DNA. In addition the results also a showed larger product than 
the expected size (101 bp) for fake maternal DNA. This was another problem 
that was highlighted for this study. 
The mix template used for the spike experiment was a 90:10 mix of maternal 
and fetal fragment respectively. However fetal fragment was purely D21S1890 
whereas maternal was genomic so there would actually have been more 
D21S1890 from fetal than maternal. This might explain why the 
electropherogram of the mix template corresponded strongly with that of the 
fetal but not of the maternal; when PCR was ran with a Td of 95°C the mix was 
expected to correlate more strongly with the maternal but this was not the case 
(Figure 12 A and B). 
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RT-PCR quantification method has many advantages over the conventional 
quantifications in terms of accuracy, sensitivity, dynamic range, high-throughput 
capacity, and absence of post-PCR manipulations. Sequence-specific 
fluorescence-labelled probes (e.g. TaqMan) have been considered as a 
standard detection format in many diagnostic and research applications, but are 
not very well suited for quantification of a large number of different sequences, 
because a new and relatively expensive probe is generally required for each 
amplicon under investigation (Freeman et al., 1999, Ponchel et al., 2003, Heid 
et al., 1996). 
Analysis of spiking products on an acrylamide gel (Figure 11) also 
suggested that the size of amplicon resulting from the fake maternal DNA 
template was larger than expected. Running spiking experiment on genetic 
analyser for fragment analysis also showed decreased number of maternal 
peaks at a critical denaturation temperature of 80 °C (i.e. not complete absence 
of fake maternal DNA peaks) (Figure 12). 
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SYBR Green for melt curve analysis was performed to confirm if we were 
getting single specific products, and also to check if we were getting the same 
melting temperatures for templates at denaturation temperatures of 95 °C and 
80 °C. Melt curve analysis was carried out for spiking experiment products 
using gradient options on StepOnePlus software, at denaturation temperatures 
of 95 °C and 80 °C. Nevertheless SYBR Green based RT-PCR is less specific 
(detects all double stranded DNA including primer-dimers and other undesired 
products) so the chance of getting heteroduplex is more when there is reduction 
in the specificity (Thompson et al., 2002). 
The amplification plot of fake maternal DNA with SYBR Green assay at a critical 
denaturation temperature of 80°C in Figure 13 B indicates possible 
heteroduplex formation, as the same fragments showed no amplification at the 
same temperature with TaqMan mastermix and probe. Melt curve analysis 
result showed different melting temperature between fake fetal DNA and spike 
sample at a critical denaturation temperature of 80 °C (Figure 14), in addition to 
shoulder peaks for all templates at the same critical denaturation temperature. 
These peaks could have been generated also by heteroduplex formation. 
Genomic DNA exists in the form of homoduplexes, with all corresponding base 
pairs being complementary, Adenine: Thymine (A: T) and Cytosine: Guanine 
(C: G). Heteroduplexes occur when dsDNA contains noncomplementary base 
pairs. Heteroduplexes arise during the plateau stage when dsDNA is more likely 
to be formed by hybridization than extension. (Palais, 2007a). 
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Upchurch, Shankarappa & Mullins (2000) has defined heteroduplexes as DNA 
molecules which have mismatched or unpaired bases. These heteroduplexes 
can be formed in vivo in several ways, such as by replication errors, during 
genetic recombination between similar but not identical DNA strands, or by 
spontaneous or chemical modification of bases. The heteroduplexes are more 
structurally unstable than the homoduplexes due to mismatches and unpaired 
nucleotides. These structural differences cause heteroduplexes to have 
reduced mobilities compared to those of the homoduplexes. The resulting 
reduction in band mobility and peak mobility can be detected by polyacrylamide 
gel electrophoresis and capillary electrophoresis, respectively. 
Homoduplex molecules migrate faster through the gel in comparison to the 
heteroduplex molecules, which move at a slower rate and often produce a 
second band below the amplification product (White and Kusukawa, 1997). This 
can be observed in Figure 6 B in this study. Janse, Bok & Zwart (2004) 
identified that a longer final elongation period and a reduction in the number of 
PCR cycles can help to reduce the identification of double bands in gel 
electrophoresis. 
Heteroduplexes and homoduplexes can be differentiated by temperature 
gradient capillary electrophoresis (TGCE) by heating the amplicons so they 
partially denature during migration through capillaries. Heteroduplexes denature 
at a lower temperature and migrate more slowly than homoduplexes during 
capillary electrophoresis. A homoduplex generates only one TGCE Peak, while 
heteroduplexed samples can yield up to four peaks (Palais, 2007b). 
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Some heteroduplexes can be eliminated from PCR products by using a 
single strand cleaving endonuclease to resolve internal single strand loop 
structures. Single stranded loop structure can form because heteroduplexes 
migrate anomalously during gel electrophoresis forming additional bands on 
agarose gels, however this can be eliminated or removed by gel purification of 
the desired PCR product (Qiu et al., 2001). 
A study by Thompson et al. (2002) demonstrated a reconditioning PCR method 
to eliminate heteroduplexes which was based on the principle that formation of 
homoduplex DNA will be favoured to the exclusion of heteroduplex DNA in the 
presence of excess primer. By restoring the initial primer concentrations during 
the reconditioning PCR a denatured DNA molecule will have a higher probability 
of annealing with a primer than with a heterolog, leading to extension of 
homoduplex. By the same principle, the formation of PCR chimeras from 
annealing and extension of heterologous DNA fragments can be reduced by 
optimizing the number of amplification cycles to maintain an excess of primer 
through the end point of reaction. 
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Throughout the experiments, an indication of primer dimer formation has been 
apparent.  Primer dimers are routinely observed in PCRs. They are not derived 
from template DNA and they can complicate experimental analysis. In the PCR, 
template-independent primer interactions can take place that give rise to non-
specific products, notably primer dimers; this can be seen clearly in Figure 6 A 
(lane 4 and 5). Because primers are present at high concentrations, weak 
interactions can occur between them. Primer dimer formation can be reduced 
by careful primer design, the application of stringent conditions, the use of ‘hot-
start’ and enzyme formulations such as AmpliTaq Gold (Brownie et al., 1997). 
Alternatively PCR contamination, which is a common problem in molecular 
laboratories, can contribute to the amplification of undesired products in PCR 
assay. Another problem that we have faced throughout the experiment was 
regarding the fake fetal and maternal DNA sample (generated from female 
genomic DNA) as these samples were freeze- thawed many times during the 
period of research. Therefore heteroduplex formation, contamination and CA 
repeats could be all regarded as a reason for stutter peaks. 
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By sequencing these samples it was hoped we would be able to explain these 
secondary products and heteroduplex formation. Thus cloning was the next 
attempt to solve the problem, and also only by cloning and then sequencing we 
would be able to determine the different STR repeats for the samples.  Our 
intention was to clone the fake fetal DNA at both 95°C and 80°C denaturation 
temperatures so that we would be able to sequence and then prove if there is 
any sequence that is being deleted by carrying out PCR at a lower denaturation 
temperature. 
Our goal was to clone both templates (fake fetal and fake maternal DNA). 
However we were able to clone female genomic DNA from which fake fetal 
DNA was produced from; but unfortunately the cloning experiment was not 
conclusive for sequencing these samples as we found out later that female 
genomic DNA sample was from anonymous pooled female blood samples. 
Due to the limited time available, it was not possible to repeat the cloning 
experiment for the other template (fake maternal DNA) or using new cloning kit 
to repeat the entire cloning experiment. However the result of sequencing fake 
fetal DNA sample at denaturation temperatures of 95 °C and 80 °C, by Kelly 
Sillence, clearly showed no sequence of CA repeat region for the fake fetal 
DNA at a critical denaturation temperature of 80 °C. While at a denaturation 
temperature of 95 °C the result showed sequencing of the CA repeat region. 
This result shows that there is the possibility of hairpin loop formation, resulting 
in looping out, which is more likely to have occurred at the lower denaturation 
temperature. 
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The hairpin-loop is a secondary structural motif frequently observed in both 
DNA and RNA where there is self-complementarity in the sequence. DNA 
hairpin-loops are involved in various biological functions. McMurray (1999) 
explained that polymerase slippage occurs at repeats because directly repeated 
sequences can provide multiple sites for pairing of a complementary strand if 
the duplex becomes unpaired. However, slippage to a matching repeat tends to 
be small. This is because slippage by more than a few repeating units becomes 
energetically unfavourable, because many more bonds must be broken in the 
template than are reformed at a loop.  
COLD-PCR seems the most encouraging enrichment technique discussed but 
requires further investigation. The goal for selective cffDNA enrichment is to 
allow its use in NIPD for Down syndrome. So after identification of critical 
denaturation temperature (80°C) for samples that contain primers designed for 
chromosome 21 marker, also alternative primers will need to be designed for a 
reference chromosome (often 13, 18 or X) so that they can be run on RT-PCR. 
When fluorescent dyes or probes are incorporated into the products of PCR 
amplification, STR markers can be rapidly analysed and quantified using DNA 
sequencer analysis, which can lead to the identification of allele ratios and 
therefore subsequent diagnosis of trisomy 21 (Adinolfi et al., 1997, Lo et al., 
2007a). This method would be a lot quicker and cheaper than measuring 
relative chromosome dose by massively parallel sequencing.  
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There remains a need therefore for an improved NIPD method, which is not 
limited in the way that the known method discussed above is constrained. In 
particular it would be advantageous if the NIPD method could overcome the 
problems associated with the low fractional concentration of cffDNA present 
within maternal plasma sample. Therefore, a rapid and accurate molecular 
based detection of aneuploidy is highly desirable. Digital PCR, a pure 
quantitative approach, requires minimal sample handling and analytical step. 
Digital PCR assays are universal and are not dependent on genetic 
polymorphisms; in contrast, the most common type of QF-PCR requires multiple 
polymorphic markers. Digital PCR is also superior to FISH in that FISH is labour 
intensive as mentioned before and requires trained personnel and intact cells 
for analysis. Digital PCR is regarded as one of the more preferable approaches 
for the NIPD of Down syndrome. 
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4.2 Conclusion  
Current invasive techniques for the early prenatal diagnosis of DS, such as CVS 
or amniocentesis, are undesirable as they carry a1% risk of miscarriage. As 
compared with the present methods of prenatal diagnosis; NIPD has the 
advantage of high sensitivity with no risk for miscarriage. 
Despite issues with altered size of products in COLD-PCR, this study describes 
how the use of COLD-PCR can allow for effective amplification of fake fetal 
DNA, due to the selective discrimination against larger genomic DNA fragments 
at identified critical denaturation temperature. A number of issues require further 
investigation, such as stutter peaks, as ideally there would be no stutter peaks 
making the true fragment length easier to interpret. The different product sizes 
at different denaturation temperatures may require redesign of the primers. The 
use of an alternative polymorphism could be also investigated for example; tri- 
or tetra-nucleotide STRs. Further research also needs to focus on eliminating 
heteroduplex formation. 
Also it is crucial to validate this project by using actual clinical samples, in this 
way one will be able to see if the enrichment technique achieved by COLD-PCR 
is able to be of diagnostic value in non-invasive prenatal medicine. Large scale 
studies to validate this technique are required, before this method of PCR 
amplification can be used in conjunction with sequencing analysis for trisomy 21 
diagnosis in a clinical setting. 
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4.3 Future work: 
 Perform a larger-scale clinical study which is essential in order to enable 
the introduction of the new test into clinical practice. 
 Provide an accurate, fast, simple and cost effective test that can be 
safely used in the clinical practice. 
 Further development of the new test so it can be utilized for the non-
invasive prenatal diagnosis of other syndromes such as trisomy 13, 18 
and aneuploidies associated with chromosomes X and Y. 
 Development of non-invasive prenatal diagnosis for other diseases and 
syndromes. 
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6 Chapter Six 
6.1 Appendix 
 
 
 
Appendix A: D21S1890 STR, identifying internal primers (blue), external 
primers (green) and probe (pink), CA repeat region underlined. These primers 
were primarily used for RT-PCR. Designed by Alice Bruson (a visiting PhD 
student from Universita delgi di Padova, Italy). 
D21S1890 External Product = 229bp) 
D21S1890 Internal Product = 101bp) 
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Appendix B: RT-PCR amplification plot at a denaturation temperature 95°C, 
with different concentrations of D21S1890 primers and probe. Female genomic 
DNA was used as a template, at a final concentration of 20 ng/µl. A) 200nM of 
primer mix and 100nM of probe showing mean Ct value of 32. B) 300nM of 
primer mix and 100nM of probe showing mean Ct value of 34. C) 200nM of 
primer mix and 50nM of probe showing mean Ct value of 38 and D) 300nM of 
primer mix and 50nM of probe with mean Ct value of 37. NTC shows 
contamination in amplification plot A and C. 
C) D) 
A) B) 
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Appendix C1: 
A) RT-PCR amplification 
plot at a denaturation 
temperature of 78.8°C. 
 
 
 
B) RT-PCR amplification 
plot at 83°C. Fake fetal 
DNA (FFDNA) has mean Ct 
value of 32, undetermined 
Ct value for gDNA. NTC 
shows contamination. 
C) RT-PCR amplification 
plot at at 82°C. Fake fetal 
DNA (FFDNA) has mean Ct 
value of 28, undetermined 
Ct value for gDNA. NTC 
shows no contamination 
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Appendix C2: RT-PCR amplification plots at different denaturation 
temperatures. A) at a denaturation temperature of 81.8°C, both ffDNA and 
gDNA shows undetermined mean Ct value B) at a denaturation temperature of 
81.6°C, ffDNA has mean Ct value of 31 and gDNA has mean Ct value of 38 for 
one replicate and undetermined for other two replicates. C) At a denaturation 
temperature of 81.4°C, ffDNA has mean Ct value of 32 and gDNA has mean Ct 
value of 42. D) At a denaturation temperature of 81.2°C, ffDNA has mean Ct 
value of 22 and undetermined for gDNA. All amplifications show contamination 
in NTC lane. 
A) B) 
C) D) 
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Appendix D: Agarose gel of PCR for identifying fake maternal DNA. PCR was 
carried out using D21S1890 external forward and reverse primers and 24 gDNA 
samples from buffy coat as templates. 
A) M= DNA ladder 
Lane 1= 075D gDNA 
Lane 2= 728Q gDNA 
Lane 3= 55309 gDNA 
Lane 4= 6515N gDNA 
Lane 5= 739K gDNA 
Lane 6= 6529BgDNA 
Lane 7= 427H gDNA 
Lane 8= 9604A gDNA 
Lane 9= 747K gDNA 
Lane 10= 748I gDNA 
Lane11= 96242 gDNA 
Lane 12= 9670R gDNA   
B) M=DNA ladder 
Lane 1= 6374 gDNA 
Lane 2= 103E gDNA 
Lane 3= 524J gDNA 
Lane 4= 735S gDNA 
Lane 5= 944V gDNA 
Lane 6= 753T gDNA 
Lane 7= 631E gDNA 
Lane 8= 057D gDNA 
Lane 9= 9151 gDNA 
Lane 10= 6534H gDNA 
Lane 11= 157Q gDNA 
Lane 12= 6517S gDNA 
A) 
B) 
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Appendix E: Electropherograms from 1-20 are of 20 different gDNA samples 
from buffy coat (in blue colour) compared with female gDNA (in pink colour). 
PCR was performed with D21S1890 FAM labelled external forward and non-
labelled external reverse primers at a denaturation temperature of 95°C. This 
was to provide fragments containing STR for analysis, as in theory this fragment 
should be 229 bp in size, but as individual may have different numbers of CA 
repeats the analysis of these fragments might show allelic heterozygosity. 
Electropherograms (derived from Peak ScannerTM software), Y axis represents 
signal intensity peak height and X axis represents size in base pairs. 
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1) 
2) 
3) 
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5) 
6) 
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9) 
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15) 
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18) 
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Appendix F: Electropherograms (derived from Peak ScannerTM software), Y 
axis represents signal intensity peak height and X axis represents in size base 
pairs. PCR was carried out using AmpliTaq Gold enzyme with fake fetal and 
fake maternal DNA as templates A) with D21S1890 internal forward and 
reverse primers and B) with D21S1890 external forward and reverse primers. 
PCR with both sets of primers was performed with a denaturation temperature 
of 95°C. 
  
 
 
 
 
A) 
B) 
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Appendix G: Agarose gel of PCR with FAM labelled D21S1890 internal forward 
and reverse primers, using AmpliTaq Gold enzyme, Female and male fake fetal 
DNA and fake maternal DNA were used as templates at denaturation 
temperatures of 95°C and 80°C. The PCR was carried out with a heating step of 
master mix at 95 °C for 15 min and after that the templates were added to the 
master mix. Then the running programme continued as 95 °C/80 °C for 15 sec, 
56 °C for 1 min and 4 °C hold. M=DNA ladder, lane 1=female fake fetal DNA at 
95°C, lane 2= fake maternal DNA at 95°C and lane 3=NTC. Lane 4=female fake 
fetal DNA at 80°C, lane 5= male fake fetal DNA at 80°C, lane 6= fake maternal 
DNA at 80°C  and lane 7=NTC ( positive contamination ) 
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Appendix H: Agarose gel of PCR with Enhancer at denaturation temperatures 
of 95°C and 80°C. A) TaqMan Fast universal PCR master mix was used with 
FAM labelled D21S1890 internal forward and reverse primers. B) Same as A 
but with AmpliTaq Gold.  M= DNA ladder 
Lane 1= fake fetal DNA 
Lane 2=fake maternal DNA 
Lane 3=NTC 
Lane 4= fake fetal DNA 
Lane 5= fake maternal DNA 
Lane 6= NTC 
Lane 7= fake fetal DNA 
Lane 8= fake maternal DNA 
Lane 9= NTC 
Lane 10= fake fetal DNA 
Lane 11= fake maternal DNA 
Lane 12= NTC 
TaqMan mastermix at Td 95°C 
TaqMan mastermix + Enhancer at Td 95°C 
TaqMan mastermix at critical Td 80°C 
TaqMan mastermix + Enhancer at critical Td 
80°C 
A) 
B) 
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Appendix I: Electropherograms (derived from Peak ScannerTM software), Y 
axis represents signal intensity peak height and X axis represents size in base 
pairs. A) TaqMan universal master mix with Enhancer, at a denaturation 
temperature of 95°C. B) AmpliTaq Gold enzyme with Enhancer at a 
denaturation temperature of 95°C. 
 
 
 
 
A) 
B) 
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Appendix K1: RT-PCR amplification plot for the spike experiment, showing 
both templates, fake fetal and fake maternal DNA. A) Amplification plot at a 
denaturation temperature of 95°C, mean Ct value for fake fetal and fake 
maternal DNA were 10.27 and 25.81 respectively. B) Amplification plot at 80°C 
critical denaturation temperature. Mean Ct value for fake fetal DNA was 25.63 
and fake maternal DNA shows no amplification (undetermined mean Ct value). 
  
A) 
B) 
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Appendix K2: RT-PCR amplification plot for the spike experiment showing 
spike sample (95% fake maternal DNA + 5% fake fetal DNA) at denaturation 
temperatures of 95 °C and 80 °C. A) At a denaturation temperature of 95 °C, 
mean Ct value of spike sample was 9.49. B) At critical denaturation temperature 
of 80 °C, mean Ct value of spike sample was 27.34. At both denaturation 
temperatures NTC showed no contamination. 
A) 
B) 
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Appendix L: Agarose gel of PCR of fake maternal DNA for cloning experiment. 
D21S1890 external forward and reverse primers were used at a denaturation 
temperature of 95°C. M= DNA ladder, lane 1= fake maternal DNA (6534H).  
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*        20         *        40         *        60         *        80         *       100 
D21S1890 : TCGCCCGAGGGTCTGACCACAGATTTCCCAATCGCCACACACACACACACACACACACACACACACACACACACACGGGTTGTTTGGGAGTCAGTTGGTTT : 101 
95FF     : TCGCCCGAGGGTCTGACCACAGATTTCCCAATCGACACACACACACACACACACACACGCACACACACACACACACGGGTTGTTTGGGAGTCAGTTGGTTT : 101 
80FF     : TCGCCCGAGGGTCTGA--GAAGA------------------------------------------------------GGTTGTTTGGGAGTCAGTTGGTTT :  45 
     TCGCCCGAGGGTCTGAccacAGAtttcccaatcg cacacacacacacacacacacac cacacacacacacacacgGGTTGTTTGGGAGTCAGTTGGTTT 
 
 
 
Appendix M: Multiple alignment of DNA sequence (Chromosome 21/ Band: 21q22.3, D21S1890) for fake fetal DNA sample at 
denaturation temperatures of 95°C and 80°C. M13 primers were used for sequencing plasmid DNA samples from two random colonies of 
fake fetal DNA, one at denaturation temperature of 95°C and other at critical denaturation temperature of 80°C. These samples were 
compared with refrence sequence from D21S1890 with internal forward and reverse primers as start and end points. Yellow sections 
indicate D21S1890 forward and reverse primers, green sections indicates CA repeat region. These results clearly show no sequence of 
CA repeats at critical denaturation temperature 80 °C, while at a denaturation temperature of 95 °C shows CA repeat compatible with CA 
repeat of D21S1890 product. 
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